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ABSTRACT 
 
THE BIOACTIVE EFFECTS OF CHICORIC ACID AS 
A FUNCTIONAL FOOD INGREDIENT 
MAY 2019 
 
YE PENG 
B.S., NORTHWEST A & F UNIVERSITY, CHINA 
M.S., UNIVERSITY OF GEORGIA, ATHENS, GEORGIA 
Ph.D., UNIVERSITY OF MASSACHUSETTS, AMHERST, MA 
 
Directed by: Professor Yeonhwa Park 
 
Chicoric acid, a hydroxycinnamic acid, has been reported to possess a variety of 
health benefits, including antivirus, anti-oxidation, anti-inflammation, obesity prevention 
and neuroprotection effects. However, its role on aging and glucose homeostasis are 
largely unknown. Therefore, the bioactive effects of chicoric acid on aging and glucose 
homeostasis were determined using Caenorhabditis elegans (C. elegans) and C2C12 
myotubes, respectively. Our study showed that chicoric acid (25 and 50 µM) significantly 
extended the lifespan of C. elegans and increased median survival rates. The declines of 
pumping rate and locomotive activity, two indicators of aging, were delayed by chicoric 
acid. Chicoric acid also enhanced resistance to oxidative stress compared to the control. 
These effects were in part via AAK-2 (a homolog of AMP-activated protein kinase) and 
 vii 
 
SKN-1 (a homolog of nuclear factor erythroid 2-related factor 2). Furthermore, chicoric 
acid significantly enhanced glucose uptake and the phosphorylation of protein kinase B 
(Akt) as an indicator of insulin signaling pathway independent of insulin in C2C12 
myotubes. These effects were dependent of the phosphorylation of 5'-AMP-activated 
protein kinase α (AMPKα), via increasing the AMP/ATP ratio in C2C12 myotubes. Our 
study may suggest the potential of chicoric acid to be used as an anti-aging and anti-
diabetic bioactive compound. 
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CHAPTER 1 
INTRODUCTION 
Chicoric acid is a hydroxycinnamic acid presents in the roots of a large number of 
plants (63 genera and species), including many plants grown in the Mediterranean area 
(1), and many of these plants have been consumed traditionally as food ingredients and 
alternative medicines for some time (2, 3). Because chicoric acid is found in especially 
high amounts in chicory (Cichorium intybus), purple coneflower (Echinacea purpurea), 
and basil, the acid is often used as a marker for the quality check of herbal products from 
these plants (4). More recently, an increasing number of publications have reported the 
beneficial effects of chicoric acid in cell culture and animal studies. However, its role on 
aging and glucose homeostasis are largely unknown. 
Aging is defined as a progressive decline of intrinsic physiological functions, 
resulting in an increased risk of death (5). Considering that aging is one of the key risk 
factors associated with many chronic diseases, slowing aging is of great importance to 
prevent age-associated diseases and improve the health span of life (6). A previous study 
reported that chicoric acid extend lifespan in Caenorhabditis elegans (7), its effects on 
aging-related phenotypes and its underlying mechanisms, however, remain to be 
determined.  
Type 2 diabetes mellitus (T2DM) has been recognized as a major public health 
challenge throughout the world in recent decades (8, 9). Impaired glucose uptake in 
muscle tissues is the primary associated with hyperglycemia in T2DM (10). Previous in 
vitro studies reported that chicoric acid ameliorated insulin resistance in human hepatoma 
cells (11). However, the effects of chicoric acid on muscle cells and its underlying 
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mechanism are still unclear. Here, C2C12 myotubes, derived from murine skeletal 
muscle cells and a C57BL/6J mice model were used to determine the role of chicoric acid 
on glucose homeostasis and its underlying mechanisms were determined.  
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CHAPTER 2 
LITERATURE REVIEW 
2.1       Chicoric acid 
Chicoric acid, a hydroxycinnamic acid that is a member of the phenylpropanoid 
family, contains two caffeoyl units (2). Chicoric acid mainly presents in two forms: first, 
the most abundant natural form of chicoric acid is L-chicoric acid (Figure 1); second, the 
acid presents in the stereoisomer meso-chicoric acid (i.e., dicaffeoyl-meso-tartaric acid or 
di-E-caffeoyl-(2R-3S)-(-)-tartaric acid) (1).  
Chicoric acid is present in the roots of a large number of plants (63 genera and 
species), including many plants grown in the Mediterranean area (1), and many of these 
plants have been consumed as alternative medicines or food supplements for some time 
(2, 3). Because chicoric acid is found in especially high amounts in chicory (Cichorium 
intybus), purple coneflower (Echinacea purpurea), and basil, the acid is often used as a 
marker for the quality check of herbal products from these plants (4). The roots of 
chicory and purple coneflower are usually baked, grounded and used as a coffee 
substitute in Europe (12). In Turkey, an herbal tea made from chicory has been used 
historically for the treatment of diabetes, epilepsy, hemorrhoids, inflammation and 
digestive disorders (13). The plant roots containing chicoric acid have been used in Asian 
traditional medicine as a tonic for curing infectious diseases, inflammatory diseases, eye 
diseases, and nerves injuries (13, 14). Commercial products made from purple 
coneflower are currently popular alternative medicines widely used in North America for 
cold and flu prevention (15). More recently, an increasing number of publications have 
reported the beneficial effects of chicoric acid in cell culture and animal studies. This 
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review summarizes these health benefit studies and the underlying mechanisms of 
chicoric acid. 
 
Figure 2.1. Molecular structure of L-chicoric acid. The most abundant natural form of 
chicoric acid is L-chicoric acid, i.e., (-)-chicoric acid, 2,3-dicaffeoyl-L-tartaric acid, 2,3-
O-dicaffeoyltartaric acid, 2R,3R-O-dicaffeoyltartaric acid, or di-E-caffeoyl-(2R-3R)-(-)-
tartaric acid. 
 
2.2       The Biological effects of chicoric acid 
The main benefits of chicoric acid include antivirus, anti-inflammation, glucose 
and lipid homeostasis, neuroprotection, and anti-oxidation effects. Biological activities 
and related mechanisms of chicoric acid from in vitro and in vivo studies are summarized 
in Tables 1 and 2. 
 
2.2.1 Anti-viral effects of chicoric acid 
The first reported bioactive effect of chicoric acid is its ability to inhibit infection 
with human immunodeficiency virus 1 (HIV-1) (16). Several studies reported that 
chicoric acid inhibits infection with HIV-1 by deactivating HIV-1 integrase (16-23). 
HIV-1 integrase is a multidomain enzyme required for the integration of viral DNA into 
the host genome, a critical step in viral replication (24). The inhibition of HIV-1 
integration by chicoric acid results in the stopping virus replication, leading to increased 
T-lymphoblastoid cell viability (17-19, 21, 22). It has been further suggested that chicoric 
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acid decreases integrase binding site activity, including: the downregulation of HIV 3'-
end processing products (16), the occupation of HIV-1 integrase catalytic core (20), the 
chelation of integrase divalent cations (17), the increase of long terminal repeat circle 
formation (21), and the inhibition of integrase-mediated catalysis (18). Hu et al. (25) 
reported that the mutation of HIV integrase might result in the blocking of chicoric acid 
specific binding sites and King et al. (26) further reported that the mutation on glycine to 
serine at position 140 (G140S) of HIV integrase reduced chicoric acid’s effects on HIV 
infection, suggesting that the integrase G140S might be a target site of chicoric acid. 
There are a few studies that are using new computational techniques including molecular 
docking and quantitative structure-activity relationship (QSAR) analysis to identify the 
binding sites of chicoric acid with HIV-1 integrase (25, 27, 28). Chicoric acid binds HIV-
1 integrase at its two arms, including the s-cis/s-cis isomer and s-cis/s-trans isomer 
arrangements (27). Based on the observation that the s-cis/s-cis isomer exhibits the most 
stable binding, this site was suggested to be the target of chicoric acid to inhibit HIV 
integrase. Another study using QSAR analysis indicated that the poly aromatic rings of 
chicoric acid are central linkers in binding to  HIV-1 integrase (28). In addition to 
integrase, reverse transcriptase is another potential target of chicoric acid (23, 29), as 
chicoric acid downregulates reverse transcriptase of HIV-1 through the inhibition of the 
trans-activator of transcription, an important protein promoting HIV-1 reverse 
transcription (29). 
Although chicoric acid may be a potential treatment for HIV, there are several 
limitations of using naturally occurring chicoric acid as a treatment, such as poor stability 
and limited cell permeability due to diacid moiety (30). To overcome these limitations, 
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chicoric acid analogs have been introduced, such as an analog of a decarboxyl compound, 
while extending a caffeoyl group on 3,4,5-trihydroxycinnamoyl sidechains, which 
showed improved stability and cell bioavailability (30-32). This analog also exhibited the 
high potency against HIV integrase infectivity (30-32). 
 
2.2.2 Chicoric acid and inflammatory responses 
Chicoric acid has been found to ameliorate inflammation induced by 
lipopolysaccharides (LPS) in both cell culture and mice. Reduced inflammation was 
associated with down-regulations of nuclear factor κB (NF-κB) and tumor necrosis factor 
α (TNF-α) (33-36), which are two major regulators of inflammation responses (37-39). 
Several other pro-inflammatory factors – including nitric oxide synthase (iNOS),  
cyclooxygenase-2 (COX-2), prostaglandin E2 (PGE2), interleukin-1β (IL-1β), IL-12 and 
IL-18 have been also reported to be downregulated by chicoric acid (33, 35, 40-43). 
However, two relevant studies showed results inconsistent with the above. Matthias et al. 
(44) reported that LPS inhibited NF-κB expression, which was reversed by chicoric acid 
treatments in Jurkat E6.1 leukaemic T-cell lymphoblasts. The other reported that 
echinacea extracts (containing chicoric acid) upregulated LPS-induced TNF-α in rat 
alveolar macrophages (45). Inconsistencies may be due to dosage and types of LPS used 
(i.e., 0.1 vs. 1 μg/ml) (34, 43, 46-48) and/or other components present in treatments (36, 
49). Overall, since the pro-inflammatory factors above are related to the occurrence of 
many chronic diseases, most research suggests chicoric acid may be considered a 
preventive tool for inflammation-associated diseases (33, 35, 40-43), however, further 
evaluation is needed. 
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2.2.3 Chicoric acid and glucose metabolism 
Chicoric acid has been reported to promote glucose uptake in muscle cells and 
hepatocytes, through activating the insulin receptor substrate/ phosphoinositide 3-kinase 
/protein kinase B (Akt) pathway (11, 50, 51). Zhu et al.(51, 52) suggested that chicoric 
acid activated Akt via the AMP-activated protein kinase α (AMPKα)-dependent 
mechanism, which is a master regulator for energy homeostasis and also plays a key role 
in glucose metabolism. However, the mechanism underlying how chicoric acid induces 
AMPKα activation is not known currently. In addition to AMPKα, glucosidase, a 
digestive enzyme for carbohydrates, was reported to be suppressed by chicory (53), 
which can contribute to reduced glucose levels (54, 55). Another enzyme, protein 
tyrosine phosphatase 1B (PTP1B) negatively regulates the insulin signaling pathway by 
inhibiting the activity of insulin receptor kinase (56). Two studies with molecular 
docking showed the molecular interactions between the allosteric site of PTP1B and 
chicoric acid, which suggests chicoric acid might inhibit PTP1B and further activate the 
insulin signaling pathway (57, 58).  
In in vivo studies, chicoric acid (or leafy extracts of echinacea or basil) reduced 
streptozotocin induced-hyperglycemia in mice (50, 52, 59, 60). In these studies, the 
protection of pancreatic β-cells by chicoric acid was attributed to its regulation of 
apoptosis related-genes, including c-Jun N-terminal kinase (JNK), B-cell lymphoma 2-
associated X/B-cell lymphoma 2 (Bax/Bcl-2) ratio, and pancreatic duodenal homeobox 1 
(PDX-1) (61). In addition, as stated in the previous section, chicoric acid downregulates 
several pro-inflammatory cytokines and mediators and these metabolic inflammatory 
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cytokines are related to the impairment of glucose homeostasis (62), indicating that 
chicoric acid might improve glucose homeostasis via regulating inflammatory responses, 
including those associated with regulators COX-2, mitogen-activated protein kinase 
(MAPK), cAMP response element binding protein (CREB) and NF-κB (51, 52), 
 
2.2.4 Chicoric acid and lipid metabolism & liver function  
Chicoric acid has been found to reduce high-fat-diet-induced weight gain in mice 
(63, 64). This was in part via the inhibition of peroxisome proliferator-activated receptor-
γ (PPARγ) and CCAAT/enhancer binding protein α (C/EBPα), two critical transcription 
factors in adipocyte differentiation and lipid accumulation, while increasing the secretion 
of adiponectin (64). Similarly, a few studies suggested that chicoric acid protected the 
liver from high-fat- or alcohol-induced fat accumulation and hepatic steatosis (63-65). 
The hepatoprotective effects of chicoric acid were suggested to be due in part to a 
decrease in the Bax/Bcl-2 ratio and the inhibition of fatty acid synthase (FAS) and pro-
inflammatory cytokines, including TNF-α, IL-6, COX-2 and JNK in the liver (63, 64). 
 
2.2.5 Chicoric acid and brain function 
There is a report that chicoric acid treatment ameliorated restraint stress-induced 
behavioral despair and depression in mice (66). This neuro-protective effects of chicoric 
acid may result from its upregulation of neurotransmitters, including noradrenaline, 
dopamine, and 5-hydroxy tryptamine in the whole brain region of mice (66). Since 
restraint stress is an important factor contributing to disorders and behavioral changes 
(such as depression, memory loss, anxiety, and learning disability), the possible 
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alleviation of restraint stress by chicoric acid suggests the potential application of 
chicoric acid for the above-mentioned brain disorders (66). Others reported that chicoric 
acid protected neurons from memory impairment, amyloidogenesis, and hippocampus 
shrinkage induced by LPS and D-galactose in mice (33, 34, 67). They also found that 
chicoric acid inhibited the expression of amyloid β and its downstream enzyme, neuronal 
β-secretase 1, both of which are known factors contributing to the disruption of neural 
connectivity and neuronal death (68). Meanwhile, chicoric acid upregulated brain-derived 
neurotrophic factor, which is a canonical nerve growth factor supporting the survival of 
existing neurons and promoting the growth of new neurons and synapses (69). Although 
limited, these findings suggest the potential protective activity of chicoric acid on 
controlling the pathogenesis of neuro-degenerative diseases. 
 
2.2.6 Anti-oxidative stress effects of chicoric acid  
Oxidative stress is defined as the imbalance between the generation of reactive 
oxygen species (ROS) and a physical ability of detoxification or damage restoration 
associated with ROS (70). ROS could act as cellular massagers but cause physical 
damages through disruptions of normal cell signaling pathways (71). Chicoric acid has 
been found to have a high oxygen radical scavenging capacity, reducing the ROS level 
and protecting cells from free radical-induced cytotoxicity (34, 53, 72-75). Moreover, 
chicoric acid increased the generation of anti-oxidative enzymes that contribute to the 
reduction of ROS levels, i.e., glutathione, glutathione peroxidase, superoxide dismutase, 
chloramphenicol acetyl transferase, heme oxygenase and NAD(P)H dehydrogenase in 
various cells (15, 21, 25, 43, 49, 61, 62, 71, 76, 77). The underlying mechanism of the 
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antioxidative effects of chicoric acid is attributed to the enhanced nuclear translocation of 
nuclear factor erythroid 2-related factor 2 (Nrf-2) and the level of peroxisome 
proliferator-activated receptor-γ coactivator α (PGC-1α) (34, 73, 75). The activation of 
Nrf-2 and PGC-1α inhibit  ROS-induced cytotoxicity by upregulation of antioxidant 
response-related genes and promotion of the mitochondrial antioxidant defense system, 
respectively (78, 79). Since oxidative stress is closely related to the development of 
certain cancers and chronic diseases, all these findings suggest the potential future 
application of chicoric acid for oxidative stress-associated diseases.  
 
2.2.7 Other bioactivities of chicoric acid 
Chicoric acid at relatively higher concentrations (105-315 μM) has been reported 
to inhibit cancer cell growth via inhibiting cell proliferation, promoting cell apoptosis, 
and deactivating telomerase through upregulation of DNA fragmentation, cleaved 
caspase-9, and cleaved poly (ADP-ribose) polymerase (80).  
Another study suggested that chicoric acid ameliorated ultraviolet A irradiation-
induced dermal fibroblast senescence by the inhibition of matrix metalloproteinase-3 
activity (81). As dermal fibroblast senescence is a hallmark of intrinsic and ultraviolet-
mediated aging (77), this indicates the potential role of chicoric acid in aging.  
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Table 2.1 In vitro effects of chicoric acid in the treatment of various disorders. 
Disorders Models Dose 
(µM) 
Duration 
(hrs) 
Effects  Suggested mechanisms References 
Anti-viral 
effects 
H9 & MT-2 human T-
lymphoblastoid 
1.05-
10.5 
48 ↑ infected cell viability; 
↓ HIV-1 integrase 
activity 
↓ HIV 3'-end processing 
products 
(16) 
 H9 & MT-2 human T-
lymphoblastoid 
0.4 48 ↓ HIV-1 integrase 
activity 
↓ HIV integrase catalytic 
core 
(20) 
 MT-2 human T-
lymphoblastoid 
105 48 ↓ HIV-1 reverse 
transcriptase activity 
↓ HIV-1 envelope 
glycoprotein 120  
 
(29) 
 MT-2 human T-
lymphoblastoid 
0.4 72 ↑ infected cell viability; 
↓ HIV-1 reverse 
transcriptase activity; ↓ 
HIV-1 reverse 
transcriptase release 
N/A (23) 
 MT-2 human T-
lymphoblastoid 
25 72 ↓ HIV-1 integrase 
replication 
N/A (19) 
 MAGI human cervical 
epithelial carcinoma 
100 52 ↓ HIV-1 integrase 
activity;  
↓ HIV-1 Tat protein 
synthesis 
(82) 
 H9 & MT-2 human T-
lymphoblastoid 
0.1-
10 
24 ↓ viral replication;  
↓ HIV-1 integrase 
activity 
↑ integrase divalent 
cations chelation  
(17) 
 MT-4 human T- 70 2 ↓ viral replication cycle; ↓ HIV-1 envelope (83) 
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lymphoblastoid  
 
↓ viral entry glycoprotein 120 
 MT-2 human T-
lymphoblastoid 
4.2 72 ↑ infected cell viability; 
↓ HIV-1 integrase 
activity 
↑ long terminal repeat 
circle formation 
(21) 
 H9 & MT-2 human T-
lymphoblastoid 
50  1-4 ↓ HIV-1 integrase 
activity 
↓ integrase binding site 
activity 
(22) 
 H9 & MT-2 human T-
lymphoblastoid 
25 1 ↓ HIV-1 integrase 
activity 
↓ integrase-mediated 
catalysis 
(18) 
Glucose 
metabolism 
L6 rat myotubes & 
insulinoma-derived ISN-
1 pancreatic β cells 
200 
& 
20-
100 
 
1-2 ↑ glucose uptake;  
↑ insulin secretion 
N/A (11) 
 INS-1 pancreatic β-
cells; L6 myotubes; 
isolated hepatocytes 
(rat) 
105-
210  
1-3 ↑ glucose uptake;  
↑ insulin secretion 
N/A (50) 
 HepG2 human 
hepatoma  
100  24 ↓ insulin resistance;  
↓ NO & ROS 
↑ GLUT2 translocation;  
↑ Akt; ↓ MAPK; ↓ NF-
κB  
(51) 
 HepG2 human 
hepatoma  
 100  24 ↑ glucose uptake ↑ IRS-1; ↑ Akt; ↑ 
AMPKα; ↑ SIRT1; ↑ 
GSK-3β; ↓ CREB 
(52) 
Inflammation 
responses 
RAW 264.7 mouse 
macrophage  
4.2 
 
4 N/A ↓ NF-κB; ↓ TNF-α (36) 
 Macrophage N/A N/A ↓ cell inflammation ↓ TNF-α (35) 
 Jurkat E6.1 human 17  4 N/A ↑ NFκB (44) 
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leukemic T-cell 
lymphoblast  
 Mouse peripheral blood 
mononuclear cells 
0.5-
4.2 
4 ↑ immune homeostasis ↑ IL-2; ↑ IFN-γ; ↓ IL-4 (41) 
 BV-2 mouse microglia  80 
 
4 ↓ cell inflammation ↓ iNOS; ↓ COX-2; ↓ 
PGE2; ↓ IL-1β; ↓ TNF-α 
(33) 
 Human umbilical vein 
endothelial cells  
12.5-
100 
24 ↓ endothelial 
dysfunction; ↓ cell 
apoptosis; ↑ cell 
viability; ↓ ROS 
↑ SOD; ↑ eNOS; ↓ 
Bax/Bcl-2; ↓ cleaved 
caspase-3; ↓ MAPK; ↓ 
NF-κB 
(42) 
 HT-29 human colorectal 
adenocarcinoma 
42 12 ↓ cell inflammation ↓ NF-κB; ↓ COX-2; ↓ 
IL-1β; ↓ IL-18 
(43) 
Oxidative 
stress 
Human plasma 1 5 ↓ Cu (II)-catalyzed LDL 
oxidation 
N/A (84) 
 RAW264.7 mouse 
macrophage 
16-
32 
20 ↓ oxidative stress ↓ PGE2; ↓ TNF-α; ↓ IL-
1β; ↓ NF-κB; ↓ Akt 
(47) 
 RAW264.7 mouse 
macrophage 
N/A 20 ↓ oxidative stress & ↓ 
NO 
↑ GSH; ↓ iNOS; ↓ NF-
κB 
(48) 
 L6 rat myotubes 5-50 1 ↓ ROS  ↑ GPx; ↑ SOD; ↑ p-
AMPKα; ↑ PGC-1α 
(73) 
 RGC-5 rat retinal 
ganglion cells  
0.025 24 ↑ cell viability & 
↓ ROS 
↓ cleaved PARP; ↓ 
cleaved caspase-3 
(67) 
 RAW264.7 mouse 
macrophage 
340 19 ↓ oxidative stress ↓ MyD88; ↓ iNOS; ↓ 
TNF-α 
(65) 
 HepG2 human 
hepatoma 
100 24 ↓ NO; ↓ ROS  ↓COX-2; ↓iNOS; ↓ NF-
κB 
(51) 
 Daudi & Namalwa B 
lymphocyte; JeKo-1 
21-
105 
12-48 ↓ B cell activating factor 
belonging to the TNF 
↓ NF-κB; ↓ IκB (85) 
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mantle cell lymphoma, 
THP-1 monocytes & 
HepG2 hepatoma 
(human) 
family (BAFF) 
 BV-2 mouse microglia 80 4 ↓ oxidative stress ↓ NF-κB; ↓ MAPK; ↑ 
Nrf2 
(34) 
 SH-SY5Y human 
neuroblastoma 
50 24 ↓ oxidative stress;  
↑ cell viability 
↑ Nrf2; ↑ HO-1; ↑ NQO-
1; ↑ CAT; ↑ GSH; ↓ 
TNF-α; ↓ IL-1β; ↓ 
malondialdehyde  
(75) 
Others HL-7702 human 
hepatocytes & HepG2 
human hepatoma 
20-
200 
48 ↑ infected cell viability; 
↓ HBV activity 
 
↓ HBV surface & 
envelope antigen 
(86) 
 Caco-2 & HCT-116 
epithelial colorectal 
adenocarcinoma 
(human) 
105-
315  
24-48 ↓ cell proliferation;  
↑ cell apoptosis;  
↓ telomerase activity 
↑ DNA fragmentation; ↑ 
cleaved caspase-9; ↑ 
cleaved PARP 
(80) 
 HeLa cervical 
carcinoma & MCF-7 
breast carcinoma 
(human) 
0.05  24 ↓ doxorubicin-induced 
cell death 
N/A (87) 
 Human skin fibroblasts 2  
 
24 ↓ dermal fibroblasts 
senescence 
↓ MMP-3 (81) 
 3T3-L1 mouse 
preadipocytes 
100 48 ↑ cell apoptosis & ↓ 
mitochondrial membrane 
potential 
↑ cleaved caspase-3; 
↓ Akt; ↑ MAPK; ↓ JNK 
& ERK1/2 
(64) 
 3T3-L1 mouse 
preadipocytes 
100 24 ↑ free radical scavenging N/A (76) 
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↑ - increase; ↓ - decrease; N/A, not available. 
Acronyms: Akt, protein kinase B; AMPKα, AMP-activated Protein Kinase α; Bax/Bcl-2, B-cell lymphoma 2-associated X/B-cell 
lymphoma 2; BSO, 1-buthionine-(S,R)-sulfoximine; CREB, cAMP response element binding binding protein; CAT, chloramphenicol 
acetyl transferase; COX-2, cyclooxygenase-2; eNOS, endothelial nitric oxide synthase; ERK1/2, extracellular signal–regulated kinase 
1/2; GLUT2, glucose transporter 2; GPx, glutathion peroxidase; GSH, glutathione; GSK-3β, glycogen synthase kinase 3β; HBV, 
hepatitis B virus; HIV-1, human immunodeficiency virus 1; 4-HNE protein adducts, 4-hydroxynonenal-protein adducts; HO-1, heme 
oxygenase; IFN-γ, interferon γ; IĸB, inhibitor of kappa B; IL-1β, interleukin 1 beta; iNOS, nitric oxide synthase; IRS-1, insulin 
receptor substrate 1; JNK, c-Jun N-terminal kinase; LPS, lipopolysaccharides; MAGI, HeLa CD4+ HIV-1 LTR-β-gal cells; MAPK, 
mitogen-activated protein kinase; MMP-3, matrix metalloproteinase-3; MyD88, myeloid differentiation primary response 88; NF-κB, 
nuclear factor κB; NQO-1, NAD(P)H dehydrogenase; Nrf2, nuclear factor erythroid 2–related factor 2; LDL, low-density lipoprotein; 
PARP, poly (ADP-ribose) polymerase; PGC-1α, peroxisome proliferator-activated receptor-γ coactivator α;  PGE2, prostaglandin E2; 
ROS, reactive oxygen species; SIRT1, sirtuin 1; SOD, superoxide dismutase; Tat, trans-activator of transcription; TNF-α, tumor 
necrosis factor α. 
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Table 2.2 In vivo effects of chicoric acid in the treatment of various disorders. 
Diseases Species 
(sex) 
Models Dose 
(mg/kg/d)  
Duration 
(days) 
Effects  Suggested 
Mechanisms 
References 
Brain 
function 
Swiss albino  
mice (M) 
Restraint stress 
(Porsolt's swim 
stress & conical 
polypropylene 
tubes) 
1-2 p.o. 
 
14 ↓ behavioral 
despair;  
↑ learning ability; 
↑ neurotransmitters 
↑ norepinephrine; 
↑ dopamine; ↑ 5- 
hydroxy 
tryptamine 
(66) 
 Sprague−Dawley 
rats & ICR mice 
(M) 
Retinal damage 
(N-methyl-D-
aspartate / optic 
nerve crush) 
2 μg/eye 
intravitreal 
injection 
7 ↑ retinal ganglion 
cell viability 
↓ cleaved PARP; ↓ 
cleaved caspase-3 
(67) 
 C57BL/6J mice 
(M) 
LPS challenges 0.5 g/L 
drinking 
water  
45 ↓ memory 
impairment; ↓ 
amyloidogenesis 
↓ amyloid β (Aβ1-
42);  
↓ BACE1; ↓ 
MAPK; ↓ NF-κB 
(33) 
 C57BL/6J mice 
(M) 
LPS challenges 0.5 g/L 
drinking 
water  
45 ↓ oxidative stress 
induced neuron 
damage 
↓ MAPK; ↓ NF-
κB; ↓ iNOS; ↓ IL-
1β; ↓ TNF-α; ↑ 
Nrf2; ↑ HO-1; ↑ 
NQO-1 
(34) 
 C57BL/6J mice 
(M) 
D-glactose 
challenges 
100 i.p. 56 ↓ neuron damage;  
↓ hippocampus 
shrinkage 
↓ amyloid β (Aβ1-
42); ↑ BDNF 
(75) 
Glucose 
metabolism 
Wistar rats (M) No challenge 3-30 i.p. 4 ↑ insulin secretion; 
↓ hyperglycemia 
N/A (50) 
 Swiss mice (M) Streptozotocin 
challenge 
3 i.p. 2 hrs ↓ hyperglycemia N/A (59) 
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 Swiss mice (M) Streptozotocin 
challenge 
1-3 
i.p. 
2 hrs ↓ hyperglycemia N/A (60) 
 C57BL/6J mice 
(M) 
Streptozotocin 
challenge 
60 drinking 
water 
4 ↓ hyperglycemia; ↓ 
pancreas 
apoptosis; ↑ 
insulin secretion 
↓ JNK; ↓ Bax/Bcl-
2; ↑ PDX-1 
(61) 
Lipid 
metabolism 
& liver 
function 
C57BL/6J mice 
(M) 
High-fat diet 
challenge 
15-60 p.o. 8 ↓ body weight; ↓ 
hepatic steatosis 
↓ TNF-α; ↓ IL-6; ↓ 
COX-2; ↓ JNK; ↓ 
PPARγ; ↓ 
C/EBPα; ↓ FAS; ↓ 
ALT & AST 
(64) 
 C57BL/6J mice 
(F) 
Hepatic steatosis 
(alcohol) 
4 drinking 
water 
4 ↓ hepatic 
triacylglycerols 
↓ iNOS; ↓ 4-HNE 
protein adducts; ↓ 
TNF-α; ↓ PAI-1; ↓ 
CD11c 
(65) 
 C57BL/6J mice 
(M) 
Methionine- and 
choline-deficient 
diet challenge 
10-30 p.o. 4 ↓ hepatic lipid 
accumulation; ↓ 
lipid peroxidation; 
↓ hepatic 
ballooning, 
steatosis & 
inflammation 
↓ SREBP-1c; ↑ 
Nrf2; ↑ AMPK; ↓ 
TNF-α; ↓ MCP-1; 
↓ FAS; ↓ ALT & 
AST 
(63) 
 C57BL/6J mice 
(M) 
Streptozotocin 
challenge 
60 drinking 
water 
28 ↓ hepatic injury ↑ glycogen; ↑ 
glycolysis genes 
(Gck, Pk & Pfk); ↑ 
AMPK  
(52) 
Inflammation Sprague-Dawley LPS challenge 20 p.o. 4 ↑ phagocytic ↑ TNF-α; ↑ IFN-γ (45) 
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rats (M) activity; ↑ NO 
 Swiss albino 
mice (M) 
Restraint stress 
(conical 
polypropylene 
tubes) 
2 p.o. 14 ↑ Th1/Th2 
homeostasis;  
↑ lymphocyte 
proliferation & T 
cell population 
[cluster 
determinant 3 (+), 
4(+) & 8(+)] 
↑ CD28 & CD80; 
↓ CTLA-4; ↓ 
CD152; ↓ IL-10; ↑ 
IFN-γ; ↑ IL-2; ↑ 
IL-12 
(88) 
 Sprague-Dawley 
rats (M) 
Arthritis 
(collagen) 
8-32 p.o. 28 ↓ paw swelling; ↓ 
organ index of the 
thymus and spleen 
↓ NF-κB; ↓ TNF-
α; ↓ COX-2 
(40) 
 ICR mice (M) Anaphylactic 
shock 
(compound 
48/80) 
20 p.o. 2 hrs ↓ mortality rate; ↓ 
histamine levels in 
blood serum 
N/A (89) 
        
M – male; F - female; ↑ - increase; ↓ - decrease; N/A, not available; p.o., Per os (oral administration); i.p., intraperitoneal injection. 
Acronyms: Akt, protein kinase B; ALT, alanine aminotransferase; AMPKα, AMP-activated Protein Kinase α; AST, aspartate 
aminotransferase; BACE1, neuronal β-secretase 1; Bax/Bcl-2, B-cell lymphoma 2-associated X/B-cell lymphoma 2; BDNF, brain-
derived neurotrophic factor; CD11c, integrin α X chain protein; CD28, cluster of differentiation 28; CD80, cluster of differentiation 80; 
CD152, cluster of differentiation 152; C/EBPα, CCAAT/enhancer binding protein α; COX-2, cyclooxygenase-2; FAS, fatty acid 
synthase; CTLA-4, cytotoxic T-lymphocyte associated antigen 4; 4-HNE protein adducts, 4-hydroxynonenal-protein adducts; HO-1, 
heme oxygenase; IFN-γ, interferon γ; IL-1β, interleukin 1β; iNOS, nitric oxide synthase; JNK, c-Jun N-terminal kinase; Keap1, kelch-
like ECH-associated protein 1; LPS, lipopolysaccharides; MAPK, mitogen-activated protein kinase; MCP-1, monocyte 
chemoattractant protein 1; NF-κB, nuclear factor κB; Nrf2, nuclear factor erythroid 2–related factor 2; NQO-1, NAD(P)H 
dehydrogenase; PAI-1, plasminogen activator inhibitor-1; PARP, poly (ADP-ribose) polymerase; PDX-1, pancreatic duodenal 
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homeobox 1; PPAR γ, peroxisome proliferator activated receptor γ; ROS, reactive oxygen species; SREBP-1, sterol regulatory 
element-binding protein 1; TNF-α, tumor necrosis factor α; Th1/Th2, T helper cells 1/2. 
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2.3 Suggested molecular targets of chicoric acid 
As discussed in previous sections, chicoric acid modulates genes, transcription 
factors, growth factors, enzymes, and proteins involved in important cellular processes, 
such as virus infection, chemoresistance, inflammation, and glucose metabolism (Figure 
2.2) (11, 42, 82, 85). Among them, it is suggested that NF-κB and TNF-α are two major 
mediators of chicoric acid’s activities.  
NF-κB is a protein complex involved  in cellular responses to stress, free radicals, 
heavy metals, and bacterial or viral infections through regulating DNA transcription, 
cytokine production, and cell survival (37, 38, 90). It is known that the activity of NF-κB 
is directly suppressed by binding with the inhibitor of κB (IκB) in the cytoplasm (90). In 
contrast, the phosphorylation of IκB releases and activates NF-κB (90). Chen et al. (85) 
reported that chicoric acid deactivates NF-κB by inhibiting the phosphorylation of IκB, 
indicating that IκB may be a major regulator for chicoric acid-mediated inactivation of 
NF-κB. Alternatively, NF-κB can be activated in combination with TNF-α (37). Several 
studies reported that chicoric acid decreased TNF-α production (40, 47, 64, 65, 75), 
which might be a  contributing factor to the reduced activation of NF-κB. Chicoric acid-
related deregulations of NF-κB and TNF-α were shown to alleviate conditions such as 
autoimmune disorders, restraint stress, hepatic steatosis and neuron damage known to be 
involved in cellular inflammation and associated diseases (34-36, 40, 47, 63-65, 75).  
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Figure 2.2 Molecular targets of chicoric acid. Akt, protein kinase B; ALT, alanine aminotransferase; AMPKα, AMP-activated Protein 
Kinase α; AST, aspartate aminotransferase; BACE1, neuronal β-secretase 1; Bax/Bcl-2, B-cell lymphoma 2-associated X/B-cell 
lymphoma 2; BDNF, brain-derived neurotrophic factor; CD28, cluster of differentiation 28; CD80, cluster of differentiation 80; 
CD152, cluster of differentiation 152; C/EBPα, CCAAT/enhancer binding protein α; COX-2, cyclooxygenase-2; ERK1/2, 
extracellular signal–regulated kinase 1/2; FAS, fatty acid synthase; HO-1, heme oxygenase; GLUT2, glucose transporter 2; IFN-γ, 
interferon γ; IL-1β, interleukin 1β; iNOS, nitric oxide synthase; JNK, c-Jun N-terminal kinase; MAPK, mitogen-activated protein 
kinase; MCP-1, monocyte chemoattractant protein 1; NF-κB, nuclear factor κB; Nrf2, nuclear factor erythroid 2–related factor 2; 
NQO-1, NAD(P)H dehydrogenase; PARP, poly (ADP-ribose) polymerase; PDX-1, pancreatic duodenal homeobox 1; PPAR γ, 
peroxisome proliferator activated receptor γ; SREBP-1, sterol regulatory element-binding protein 1; TNF-α, tumor necrosis factor α; 
Th1/Th2, T helper cells 1/2. 
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2.4       Pharmacokinetic study of chicoric acid 
Chicoric acid is known to have relatively low absorption in rats (91). The oral 
administration of chicoric acid at 50 mg/kg body weight resulted in a peak plasma 
concentration of chicoric acid at 1.63 ± 0.25 mg/L after 4 h (91). Chicoric acid was 
mainly distributed in the liver, lung and kidney after oral administration for 3 h. Chicoric 
acid has a relatively long residence time and low body clearance, 18.58 ± 4.43 h and 2.80 
± 0.46 L/kg/h, respectively, in rats (91). All these findings help in better understanding 
the bioavailability and fate of chicoric acid. 
 
2.5       Conclusion 
The prevention of early-stage chronic diseases by food bioactive seems to be a 
promising strategy. Chicoric acid’s multi-bioactivities suggest it has great potential in 
treating a number of metabolic disorders, including inflammatory responses, impairment 
of energy homeostasis, brain dysfunction, and immune disorders. Even though there are 
increasing number of studies reporting bioactivities of chicoric acid, these are still 
limitations to make a concrete conclusion due to differences on models, doses, and 
treatment durations used, as well as lack of pharmacokinetic study, including metabolism, 
of chicoric acid in humans. The research on chicoric acid is still at an early stage, so there 
are still many questions that need to be answered regarding its benefits to health. Thus, 
more studies are needed to guide the development of chicoric acid-based functional food 
products.  
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CHAPTER 3 
OBJECTIVES OF THE PROJECT 
The long-term goal is to develop chicoric acid as a functional food bioactive for 
the prevention and/or treatment for aging and type 2 diabetes. Previous studies reported 
that chicoric acid extends C. elegans lifespan and promotes glucose transport in hepatic 
cells (7). However, more experiments are needed to further investigate the effects of 
chicoric acid on aging-related phenotypes in C. elegans and the glucose uptake in other 
models. The object of this project is to determine the effect of chicoric acid on the aging-
associated phenotypes of C. elegans and glucose uptake in muscle cells. The central 
hypothesis is that chicoric acid can protect C. elegans during aging as well as promote 
glucose uptake in muscle cells. The rationale of the proposed research is that by 
investigating the effect of chicoric acid on aging and glucose uptake as well as the 
underlying mechanisms, we will be able to better understand chicoric acid as a beneficial 
bioactive for the promotion of health span and prevention from type 2 diabetes. 
The project aims are as follows: 
Specific aim 1: Determine the effect of chicoric acid on aging and aging-related 
phenotypes of C. elegans. The hypothesis is that chicoric acid extends the lifespan of C. 
elegans and delays the decrease of aging-related phenotypes.  
Specific aim 2: Investigate the effect of chicoric acid on glucose uptake in muscle 
cells and mice. The hypothesis to be tested is that chicoric acid promotes the glucose 
uptake in C2C12 myotubes and reduces the blood glucose level in mice.  
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CHAPTER 4 
EFFECTS OF CHICORIC ACID ON AGING AND 
GLUCOSE UPTAKE 
4.1 Effect of chicoric acid on aging in C elegans and the underlying mechanisms 
4.1.1 Introduction 
Aging is defined as a progressive decline of intrinsic physiological functions, 
resulting in an increased risk of death (5). Considering that aging is one of the key risk 
factors associated with many chronic diseases, slowing aging is of great importance to 
prevent age-associated diseases and improve the health span of life (6). Currently, food-
derived bioactive compounds are drawing significant attention because of their anti-aging 
effects and the modulation of aging-related pathways (92-95), which provide potentially 
valuable preventive tools for aging and aging-related disorders.  
Chicoric acid, one of the hydroxycinnamic acids, is a dicaffeoyl ester naturally 
found in the roots of many plants, such as chicory, purple coneflower, and basil (4). 
Chicoric acid is reported to have a number of bioactivities, including antioxidation, anti-
inflammation, antivirus and immune-stimulating properties through multiple molecular 
pathways (18, 33, 41, 52). A previous study reported that chicoric acid extended the 
lifespan in Caenorhabditis elegans (7), however, the effects of chicoric acid on aging-
related phenotypes and the mechanisms underlying these effects remain to be determined. 
 One recent study reported that chicoric acid regulates glucose metabolism via 
AMP-activated protein kinase (AMPK) activation (52). AMPK is an energy sensor that 
controls energy homeostasis through the regulation of AMP/ATP metabolism in cells (4). 
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Moreover, AMPK is considered important in the regulation of longevity as the increased 
activation of AMPK extended the lifespan through dietary restriction and/or enhanced 
stress resistance in C. elegans and Drosophila melanogaster (96, 97). aak-2, a homolog 
of the α-catalytic subunits of mammalian AMPK, is evolutionarily conserved in both C. 
elegans and mammals (98). Since AMPK has been reported to be activated by chicoric 
acid (52), it is plausible to assume that chicoric acid might regulate the lifespan of C. 
elegans via aak-2. In addition to aak-2, skn-1, encoding a homolog of nuclear factor 
erythroid 2–related factor 2 (Nrf-2) in C. elegans, was also reported to extend lifespan by 
regulating the oxidative stress response pathway (99). Therefore, the current research 
focused on determining the influence of chicoric acid on aging-related phenotypes in C. 
elegans and the role of AAK-2 and SKN-1 in this process. 
 
4.1.2 Materials and methods 
4.1.2.1 Materials 
Chicoric acid (≥ 98%) was purchased from PufeiDe Biotech Co., Ltd (Chengdu, 
Sichuan, China). Household bleach used for bleaching adult nematodes during 
synchronization was obtained from Clorox company (Oakland, CA, USA). 
Fluorodeoxyuridine (FUdR), ampicillin, and carbenicillin, paraquat, and 2’,7’-
dichlorodihydrofluorescein diacetate (DCFDA) were ordered from Sigma-Aldrich (St. 
Louis, MO, USA). Rabbit antibodies for phospho-AMPK and α-tubulin, as well as goat 
anti-rabbit IgG-horseradish peroxidase (HRP) were obtained from Cell Signaling 
Technology (Danvers, MA, USA). Rabbit antibodies for phospho-AMPK and α-tubulin, 
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as well as goat anti-rabbit IgG-horseradish peroxidase (HRP), were obtained from Cell 
Signaling Technology (Danvers, MA, USA). 
 
4.1.2.2 C. elegans: strains and maintenance 
The strains in the study were provided by the Caenorhabditis Genetics Center 
(CGC, University of Minnesota, Minneapolis, MN, USA): wild-type Bristol N2, aak-2 
(ok524) X, daf-2 (e1370) III, eat-2(ad1116) II, daf-16(mgDf50) I, skn-1(zu135) IV, age-
1(hx546), and ldIs7 (skn-1b/c::gfp; rol-6). All strains were grown and incubated at 20 °C 
on nematode growth media (NGM) plates with Escherichia coli OP50, except daf-2, 
which was maintained at 15 °C. The solutions including nematode growth medium 
(NGM), M9 buffer, and S-complete required for C. elegans culture were prepared 
according to the worm book (100). A synchronized culture was obtained as previously 
described (101). The chicoric acid stock solutions with 12.5, 25, and 50 mM were 
prepared using dimethyl sulfoxide (DMSO) as solvent. Stock solutions were diluted 1000 
times resulting in final concentrations of chicoric acid at 12.5, 25, and 50 M. These 
doses were based on a previous report on the effects of chicoric acid on life span 
extension in C. elegans (7). For lifespan analysis, L4 stage nematodes were transferred in 
Transwell-96 well plate (Corning Inc., NY, USA; n=10-15 worms per well, 15-18 wells/ 
treatment) and treated with 0.1% DMSO (control) or chicoric acid during the lifespan 
study (94, 102, 103). FUdR (120 mM), to prevent eggs from hatching out, was also added 
(104). The medium was changed every four days. The survivals were determined by a 
gentle touch-prod with a sterilized picker under a microscope (Nikon Instruments Inc., 
Melville, NY, USA) (94, 103).  Worm viability was recorded every other day until all 
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worms died. The day that the treatment began is considered as day 0. The lifespan test in 
N2 was repeated for three independent trials. 
 
4.1.2.3 Growth rate, body size, and moving speed determination 
The growth rate of C. elegans was determined by quantifying the population of 
worms at three different developmental stages after 48 h chicoric acid treatments. Results 
were shown in percent of proportion of C. elegans in each stage (94). Body size and 
moving speed of C. elegans were measured by the WormLab tracking system (Allied 
Vision Technologies, Stadtroda, Germany) and analyzed by WormLab Software (MBF 
Bioscience, Williston, VT, USA) as published (101). Worms were transferred to the low-
peptone NGM plates seeded with OP50 and were undisturbed for 30 min for acclimation 
before tracking (94). A 1-min recording (8.12 frames per second) was captured. The size 
of the worms (70-90/treatment) was measured by the WormLab Software after 48 h of 
treatments. The moving speed of worms was measured every other day from day 2 to day 
12. 
 
4.1.2.4 Progeny production and pumping rate determination 
After 48 h chicoric acid treatments, two L4 staged nematodes/treatment were 
shifted to freshly prepared NGM plates with E. coli OP50 every day during the 
reproduction period. The number of progeny hatching out of eggs was counted and 
recorded daily (94). The pumping rate was obtained by quantifying pharyngeal 
contraction times of nematodes using a microscope (Olympus Corporation, Tokyo, Japan) 
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for 30 sec. The test was repeated three times with 12 randomly-selected nematodes per 
treatment (94).  
 
4.1.2.5 Measurement of intracellular ROS and oxidative stress resistance 
The intracellular reactive oxygen species (ROS) level was detected using 
DCFDA, a fluorescent probe commonly applied for ROS detection (105). After a 72-h 
treatment with DMSO (control group) or chicoric acid, day 1 adult nematodes were 
washed with M9 buffer three times to remove bacteria. They were next transferred into a 
96-well plate, ~60 worms/well, with or without chicoric acid treatments in 50 µL of M9 
buffer, following the mixture of 50 µL DCFDA solution (200 µM) to achieve 100 µM of 
the final concentration. A well with 100 µM DCFDA solution with no worms was used as 
the background, and worms treated with DCFDA solution and 5 mM paraquat were used 
as the positive control. The fluorescent readings were taken after 30 min of incubation at 
an emission/excitation wavelength of 530 and 485 nm by an Infinite 200 PRO microplate 
reader (Tecan Trading AG, Switzerland). 
For oxidative stress resistance determination, day 1 adult worms were transferred 
into the 96 trans-well plate, 12-15 worms per well, containing 5 mM paraquat, an 
oxidative stress inducer. The oxidative stress resistance of C. elegans was determined by 
counting the survival percentage of worms under the exposure of paraquat for 2, 4, and 6 
days with or without chicoric acid treatment (i.e., 25 µM) (94). 
 
4.1.2.6 Quantitative real-time PCR 
RNA was extracted in each sample using Trizol under RNase-free conditions, as 
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previously described (101). cDNA was prepared by reverse transcription of mRNA using 
a high-capacity cDNA reverse transcription kit (Thermo Fisher Scientific Inc, 
Middletown, VA, USA). The gene expression was quantified by QuantStudio 3 real-time 
PCR system using the TaqMan detection assay (Applied Biosystems, Waltham, MA, 
USA). aak-2 (Ce02404259_g1), nhr-49 (Ce02412666_g1), skn-1 (Ce02407444_m1), gsr-
1 (Ce02444754_g1) and pbs-5 (Ce02426103_g1), and the internal control ama-1 
(Ce02462726_m1) were ordered from Thermo Scientific (Middletown, VA, USA).  
 
4.1.2.7 Intracellular localization of SKN-1::GFP 
Transgenic strain ldIs7 (skn-1b/c::gfp; rol-6) was used to detect the intracellular 
localization of GFP tagged SKN-1 protein. After two-day of chicoric acid treatment (25 
µM), around 10-20 worms (L4 stage or young adults) were placed on each microscope 
slide coated with 2% agarose pad and anesthetized with 10 mM NaN3 within 3 min (94). 
Worms treated with NaN3 (2%) for 15 min were used as the positive control. The cellular 
localizations of SKN-1 were detected by a Nikon Eclipse Ti-U (Nikon Instruments Inc., 
Melville, NY, USA). The nuclear translocation patterns of SKN-1::GFP were identified as 
‘low’, ‘medium’, and ‘high’. ‘Low’ refers to worms with almost no visible nuclear 
translocation; ‘medium’ refers to C. elegans with nuclear translocation in the partial 
body; ‘high’ refers to worms with nuclear translocation throughout the whole body, as 
shown in Figure 4.6D.  Worms were counted and analyzed as percentages of nuclear 
translocation including both ‘medium’ and ‘high’ translocation (103). 
 
4.1.2.8 Western blotting 
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The C. elegans protein extraction was obtained according to the protocol 
published with minor modification (101, 106). Worms were collected and washed four 
times with M9 buffer to remove bacteria. Then worms (approximately 6000 young adults 
per sample) were suspended by 500 µL PBS mixed with protease and phosphatase 
inhibitors (Beyotime Biotechnology, Shanghai, China). Samples were homogenized and 
centrifuged (12,000 × g) at 4 °C for 10 min to harvest the supernatants. After protein 
normalization, the samples with 5 × sample buffer were electrophoresed on a 10% SDS 
polyacrylamide gel and transferred onto a polyvinylidine fluoride membrane (107). After 
blocking with 5% skim milk, the membrane was incubated with rabbit monoclonal anti-
phospho-AMPK and rabbit anti-α-tubulin antibody. Horseradish peroxidase-conjugated 
goat anti-rabbit IgG was used as the secondary antibody. Protein blots were pictured by a 
Tanon 5500 image station (Shanghai, China) with ECL Substrate Kit (Bio-Rad Co., 
Hercules, CA, USA). Images were quantified with ImageJ software. 
 
4.1.2.9 Statistical analysis 
Survival curves were analyzed by Log-rank (Mantel-Cox) tests by Graph Pad 
Prism version 6.0 (GraphPad Software, Inc., San Diego, CA, USA). The data of nuclear 
translocation of SKN-1::GFP in Fig. 4.6D was analyzed by chi square tests by SAS 
software (version 9.3, SAS Institute Inc., Cary, NC, USA). For other data, differences 
between each treatment were analyzed using one-way ANOVA (Tukey’s multiple-range 
test, SAS). Significance of differences was defined as P values of < 0.05.  
 
4.1.3 Results 
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4.1.3.1 Chicoric acid extended the lifespan of C. elegans 
Compared with the control, chicoric acid at 25 and 50 µM, but not 12.5 µM, 
significantly extended the lifespan of wild type nematodes (P<0.0001 for both; Fig. 1). 
There was no difference in lifespan between 25 and 50 µM chicoric acid treatments. 
Table 1 also exhibited the extended median lifespan of wild type N2 worms with 25 and 
50 µM chicoric acid treatment, compared to the control. This was consistently observed 
from 3 independent experiments: (median lifespan as days) 18.7±0.3 for control, 
23.3±0.9 for 25 µM chicoric acid, and 22.7±0.7 for 50 µM chicoric acid with P=0.0062 
and P=0.0128 for 25 and 50 µM chicoric acid compared to the control, respectively. 
Thus, 25 and 50 µM were used to determine the aging-related phenotypes. 
 
Figure 4.1 Survival of wild-type C. elegans treated with chicoric acid. C. elegans (N2) 
were treated with final concentrations of 0 (control), 12.5, 25, or 50 µM chicoric acid 
starting from L4 stage (day 0). The survivals were recorded every other day until all the 
worms died (n = 206–266/treatment). Log-rank (Mantel-Cox) test was used for statistical 
analysis. Significant differences of median/maximum lifespan compared between the 
control and the treatment groups were marked as ***P<0.001. 
 
The physiological properties of C. elegans treated by chicoric acid after 
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synchronization were determined by growth rate, body size, and progeny (Fig. 4.2). After 
48 h of treatment, 76–80% of the nematodes reached L4 stage or young adult stage, while 
20–23% were at early/mid L4 stage (Fig. 4.2A). As shown in Fig. 4.2, no difference was 
observed in the growth rate, worm length, worm width, or progeny number of C. elegans 
treated with or without chicoric acid. The results suggest that the physiological properties 
of nematodes were not affected by chicoric acid. 
 
Figure 4.2 Effect of chicoric acid on growth rate, worm size and progeny production of 
C. elegans. (A) Synchronized L1 worms were raised on NGM plates with 0, 25 and 50 
µM chicoric acid. After 48 h treatments, the number of worms at three developmental 
stages was counted and calculated in percent of proportion. (B) Synchronized L1 larval 
worms were treated with chicoric acid and the number of progeny hatching out from day 
1 to day 5 were recorded. (C) Worm length and (D) width were measured by WormLab 
software after 48 h treatments from the L1 stage. Values are means ± S.E. (n = 3 plates 
and ~150 worms/plate for growth rate; n = 3 plates and 2 worms/plate for progeny 
production, n = 140–180 for worm size). 
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4.1.3.2 Effect of chicoric acid on the age-associated decline of phenotypes and ROS 
levels 
Two typical markers of aging-relative phenotypes in C. elegans are pharyngeal 
pumping rate and locomotive activity (102). Thus, we next detected the effects of 
chicoric acid on these two markers (Fig. 4.3). The pumping rate as expected declined 
progressively with aging: 60% decline of the pumping rate in the control group from day 
4 to day 12 (Fig. 4.3). Chicoric acid treatments with both 25 and 50 µM statistically 
delayed the decrease of pumping rate compared to the control (Fig. 4.3A). A significant 
difference was first observed on day 6, and a greater difference was found on day 12 
(29.1% and 32.9% improvement, respectively, compared to the control). Aging resulted 
in the decline of moving speed by 76.4% on day 12, compared with that of day 2 in the 
control (Fig. 4.3B). Consistent with changes in the pumping rate, the decline in 
locomotive activity of the worms was lessened by chicoric acid treatments; On day 12, 
chicoric acid-treated C. elegans moved 59% and 86% faster than the control group, 
respectively (Fig. 4.3B). 
 
Figure 4.3 Chicoric acid ameliorated the age-related decline of movement and pumping 
rate. (A) Synchronized L1 C. elegans were treated with chicoric acid and pharyngeal 
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pumping was counted every other day until day 12. (B) Synchronized L1 C. elegans were 
treated with chicoric acid and moving speed was recorded by WormLab tracking system. 
Then the average moving speed of each worm was calculated using WormLab Software. 
Values are means ± S.E. n = 12 worms for pumping rate; n = 140–180 for worm speed. 
Values with different letters at each point in time are significantly different (P < 0.05). 
 
Previous studies have reported that extended lifespan is closely associated with 
increased resistance towards oxidative stress (93, 94, 96). Since chicoric acid is known to 
possess anti-oxidative properties, the intracellular ROS levels of C. elegans were 
determined after the treatment of chicoric acid. The intracellular ROS levels in the 
chicoric acid treatment groups were significantly reduced (14.6% and 19.2% for 25 and 
50 µM chicoric acid with P=0.0392 and P=0.0134, respectively) compared with the 
control (Fig. 4.4). 
 
Figure 4.4 Effect of chicoric acid on the oxidative stress sensitivity of wild type N2 
worms.  Relative formation of reactive oxygen species (ROS) after 72 h of exposure to 
chicoric acid (0, 25 or 50 μΜ). Paraquat (5 mM) was used as the positive control. Values 
are means ± S.E. (n = 9; 60 worms/well). Values with different letters are significantly 
different (P<0.05). 
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4.1.3.3 Extended lifespan by chicoric acid required AAK-2 and SKN-1 
Several studies reported that aak-2 is an essential regulator in the aging of C. 
elegans through dietary restriction and/or stress resistance (96, 108-110). aak-2 encodes a 
homolog of the catalytic-α subunit of AMPK in C. elegans. The deletion of aak-2 
shortens C. elegans lifespan, while the overexpression of aak-2 results in C. elegans 
lifespan extension (108, 109). Since chicoric acid has been found to upregulate AMPK in 
hepatocytes (52), we determined the role of AMPK homolog in chicoric acid’s effects on 
lifespan extension using aak-2 loss-of function mutants. As shown in Table 4.1 and Fig 
4.5A, the deletion of aak-2 abolished chicoric acid-mediated lifespan extension, 
indicating the requirement of aak-2 in C. elegans-lifespan extension by this compound.  
In addition to aak-2 , it is known that the insulin/IGF-1 signaling pathway is 
involved in aging in nematodes (111, 112). daf-2 encodes for the insulin-like growth 
factor 1 (IGF-1) receptor, which is an important regulator for aging in nematodes (113). 
Mutants deficient in daf-2 exhibit longer lifespan due to an extended dauer stage (114). 
One of the downstream targets of daf-2 is age-1, another gene mainly regulating the 
longevity of C. elegans (113). Furthermore, DAF-2 and AGE-1 have been reported to 
inhibit DAF-16, an important transcription factor that regulates C. elegans’ lifespan (94). 
To determine whether chicoric acid extends lifespan through the insulin signaling 
pathway, we tested daf-2, age-1, and daf-16 null mutants. The daf-2 deficient and age-1 
deficient mutants treated with 25 and 50 µM chicoric acid displayed significantly 
extended median lifespan compared to the respective controls (P<0.0001 for both; Table 
4.1 and Fig 4.5B-C). Similarly, the median lifespan of daf-16 mutants was significantly 
extended with the exposure of both 25 and 50 µM chicoric acid compared to the control; 
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14 days for the control (daf-16 mutants) vs. 18 and 20 days with chicoric acid at 25 and 
50 µM, with P=0.0012 and P=0.05, respectively (Fig 4.5D). These results indicate that 
chicoric acid may act independently of the insulin/IGF-1 signaling pathway in C. elegans 
(113).  
In addition to AMPK and the insulin signaling pathway, several other molecular 
targets are known to regulate C. elegans lifespan, such as SKN-1 and EAT-2. SKN-1/Nrf-
2 transcription factor has been found to mediate C. elegans lifespan extension mainly 
through the oxidative stress response pathway (115, 116). From Table 4.1 and Fig 4.5E, 
skn-1 mutation abolished chicoric acid-induced lifespan extension, suggesting that skn-1 
is required for chicoric acid-mediated lifespan extension. Lastly, we tested eat-2 mutant, 
which has defects of pharyngeal pumping that leads to prolonged lifespan via dietary 
restriction pathway (117). As shown in Table 1 and Fig. 4.5F, chicoric acid treatments 
shortened the median lifespan of eat-2 deficient mutant, indicating the extended lifespan 
by chicoric acid might not occur through modulation of dietary intake. Since the 
observations that 25 and 50 µM chicoric acid led to similar effects on the aging and 
lifespan of mutants, we used 25 µM chicoric acid for the rest of the experiments.  
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Table 4.1 Effect of chicoric acid on median lifespan of wild type and mutant C. elegans. 
Strain 
Chicoric acid 
treatment (µM) 
Median lifespana 
(days) 
Genetic 
requirementb 
N2 Control 19 - 
 25 23***  
 50 22***  
aak-2 (ok524) X Control 12 Yes 
 25 12  
 50 14  
daf-2 (e1370) III Control 32 No 
 25 36***  
 50 38***  
age-1 (hx546) II Control 28 No 
 25 32***  
 50 32*  
daf-16 (mgDf50) I Control 14 No 
 25 18**  
 50 20***  
skn-1(zu135) IV Control 16 Yes 
 25 18  
 50 18  
eat-2(ad1116) II Control 32 No 
 25 24***  
 50 26*  
All strains were raised at 20 C, except daf-2 (e1370) III, which was raised at 15 °C. 
Worms were treated with chicoric acid (25 or 50 µM) from the L4 stage (day 0). 
Floxuridine (FUdR) was added with a final concentration of 120 µM. The survivals were 
recorded every other day until all the worms died. a The median lifespan was referred to 
the time when survival rate dropped to 50%. *, **, and *** mean significant difference 
compare with their respective control at P<0.05, P<0.01 and P<0.001, respectively (n = 
180–266 worms/treatment). b Significant differences were analyzed by Log-rank (Mantel-
Cox) tests. Genetic requirement was defined as “Yes” at P<0.05 or “No” at P>0.05. 
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Figure 4.5. Survival of several mutant strains treated with chicoric acid. (A-F) Loss of 
function mutant strains in several genes related to lifespan regulation were treated with 
final concentrations of 0 (control), 25, or 50 µM chicoric acid starting from L4 stage (day 
0). The survivals were recorded every other day until all the mutants died (n = 180–266 
worms/treatment). Log-rank (Mantel-Cox) test was used for statistical analysis.  
 
4.1.3.4 Chicoric acid might extend C. elegans lifespan via the regulation of AAK-2 
and SKN-1. 
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Since the loss of aak-2 and skn-1 abolished chicoric acid-mediated lifespan 
extension, we determined the role of aak-2 and skn-1 in chicoric acid’s effect on lifespan 
extension. First, we found that chicoric acid upregulated the mRNA expression of aak-2 
(Fig. 4.6A). Since it is known that AAK-2 can be regulated post-translationally (97, 118, 
119), we measured the role of chicoric acid in phosphorylation of AAK-2 and found that 
chicoric acid significantly increased the phospho-AAK-2 level (P<0.001, Fig. 4.6B and 
C). We further determined the mRNA expression of a downstream target of AAK-2, nhr-
49, a homolog of peroxisome proliferator-activated receptor alpha (PPARα) (120). As 
shown in Fig. 4.6A, chicoric acid treatment significantly increased expression of nhr-49 
compared to the control (P=0.0066). 
Chicoric acid also significantly upregulated gene expression of skn-1 (Fig. 4.6A). 
Similar to AAK-2, SKN-1 can be regulated post-translationally, which can be measured 
by nuclear translocation of SKN-1 in C. elegans (121). Chicoric acid treatment 
significantly promoted SKN-1 translocation from the cytoplasm to the nuclei (P=0.0041, 
Fig 4.6D), suggesting potential post-translational regulation of SKN-1 by chicoric acid. 
Next, we further tested two SKN-1 target genes, gsr-1 (glutathione reductase) and pbs-5 
(proteasome beta subunit) (122-124), which were increased by chicoric acid treatment – a 
1.7-fold and 2.4-fold increase over the control, with P=0.0259 and P=0.0112, 
respectively (Fig. 5A). 
 40 
 
 
 
Figure 4.6 Chicoric acid might extend C. elegans lifespan via the regulation of AAK-2 
and SKN-1. Synchronized L1 worms were treated with 0 or 25 µM chicoric acid for 48 h 
(A). The mRNA expression of aak-2, nhr-49, skn-1, gsr-1, and pbs-5 were determined by 
real-time PCR. ama-1 was used as an internal control. (B) Phospho-AAK-2 and tubulin 
were determined by immunoblotting. (C) p-AAK-2/Tubulin, phospho-AAK-2/Tubulin. 
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Values are means ± S.E. (n=3), *P<0.05, **P<0.01, and ***P<0.001. (D) Intracellular 
localization of SKN-1::GFP. The nuclear translocation patterns of SKN-1::GFP were 
identified as ‘low’, ‘medium’ and ‘high’. (E) Nuclear translocation of SKN-1 in ldIs7; 
worms treated with chicoric acid were analyzed using the chi square test, and therefore 
do not show standard error bars (control, n=94; NaN3, n = 82; chicoric acid 25 μM, n = 
107). A NaN3 (2%) treated group was used as the positive control. ** and *** mean 
significant difference compared with the control at P<0.01 and P<0.001, respectively. 
 
4.1.3.5 Chicoric acid enhanced oxidative stress resistance in wild type N2 worms but 
not aak-2 mutants 
As aak-2 has been reported to regulate oxidative stress resistance in nematodes 
(119), we then evaluated the influence of chicoric acid on oxidative stress responses of 
wild type worms and aak-2 mutants. After 2, 4, and 6 days of paraquat exposure, the 
survival of chicoric acid-treated wild type worms was consistently improved over that of 
the control (12.2%, 12.8%, and 20.8% improvement for 25 µM chicoric acid with 
P<0.001, P=0.002, and P<0.001, respectively, Fig 4.7A). As shown in Fig 4.7B, the 
beneficial effect of chicoric acid against oxidative stress was abolished in aak-2 mutants, 
suggesting an essential role of AAK-2 in chicoric acid-enhanced oxidative stress 
resistance in C. elegans.  
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Figure 4.7 Chicoric acid enhanced the stress resistance of wild type worms but not aak-2 
mutants. Wild type worms and aak-2 mutants (day 1 adults) were exposed to 5 mM 
paraquat with or without chicoric acid for 2, 4, and 6 days and survivals were counted. 
Values are means ± S.E. (n = 3; 120-145 worms/treatment), **P<0.01 and ***P<0.001. 
 
4.1.4 Discussion 
In the current study, we found that chicoric acid at 25 and 50 µM significantly 
extended the lifespan of C. elegans. These findings are consistent with a  previous study 
showing that chicoric acid at 25 µM or higher concentrations extended C. elegans 
lifespan (7). Here, we further investigated that chicoric acid-induced lifespan extension 
was accompanied by the prevention of age-associated declines of pumping rate and 
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locomotor activity as well as reduced oxidative stress sensitivity without influencing 
other physiological functions. The effects of chicoric acid was determined to be mediated 
in part by cellular energy sensor, AAK-2, and oxidative stress responsive transcription 
factor, SKN-1, but not via the insulin signaling pathway or dietary restriction.  
C. elegans lifespan extension is closely associated with enhanced stress 
resistance, including oxidative stress (125). Increased oxidative stress, resulting from the 
excess production of free radicals, typically ROS, accelerates the aging of C. elegans 
(70). Here, we found that chicoric acid reduced ROS level in vivo and increased survivals 
under an oxidative stress condition, which is consistent with previous reports that 
chicoric acid reduced ROS and enhanced oxidative stress resistance in RGC-5 rat retinal 
ganglion cells and SH-SY5Y human neuroblastoma (67, 75). Antioxidative compounds, 
including chicoric acid, may directly act as ROS scavenger and/or indirectly activate 
stress-related signaling pathways, although based on the current results, it is not clear 
how chicoric acid elicits its effects on ROS.  
The aak-2 gene encodes an isomer of the AMPKα in C. elegans (108). A few 
studies have reported that aak-2 is intimately involved in the control of C. elegans 
lifespan through the regulation of dietary restriction and/or stress resistance (96, 108-
110). Based on the significant effect by chicoric acid on eat-2 mutants, we determined 
that chicoric acid elicits its protective effects via stress resistance. In particular, Lee et al. 
(119) reported that aak-2 mutations are hypersensitive to paraquat-induced oxidative 
stress, suggesting an important role of aak-2 to C. elegans oxidative stress responses. 
This is supported by the current observation that aak-2 deficiency completely abolished 
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the chicoric acid-mediated lifespan extension and survival during the oxidative stress 
conditions in C. elegans (Table 4.1 and Fig.4.5). The nhr-49 is one of the downstream 
genes of aak-2 (120), and it was suggested that NHR-49 may participate in oxidative 
stress responses and prevent ROS-induced toxicity in C. elegans (121). In fact, Moreno-
Arriola et al. suggested that phospho-AAK-2 can regulate oxidative metabolism through 
increased transcriptional activity of nhr-49 (126). Thus, chicoric acid may extend lifespan 
in part via a mechanism dependent upon aak-2 and its target, nhr-49. However, since we 
were not able to determine the effects of chicoric acid on AAK-2 due to lack of available 
antibodies for AAK-2 of C. elegans, it is not conclusive that chicoric acid upregulated 
AAK-2 transcriptionally and/or post-translationally with the current results only. 
skn-1 is also involved in chicoric acid-induced lifespan extension in C. elegans. 
SKN-1 starts regulating C. elegans lifespan as early as the postembryonic stage by 
activating cellular defense responses to oxidative stress (127). This was further supported 
by the fact that loss of function mutants in skn-1 are sensitive to oxidative stress and the 
transgene of SKN-1::GFP rescues their embryonic developmental defect (115). It was 
reported that nuclear translocation of SKN-1 results in the higher cellular oxidative stress 
resistance in C. elegans (121). The current study showed that chicoric acid induced 
translocation of SKN-1 from the cytoplasm to nuclei with minimum enhancement of skn-
1 expression. This may suggest that chicoric acid’s effect on post-translational regulation 
of SKN-1 contributes significantly to the antioxidation and lifespan benefits of chicoric 
acid in C. elegans. This was further confirmed by the observation of increased expression 
with chicoric acid treatment of two downstream genes of SKN-1, glutathione reductase 
(gsr-1) and proteasome subunit (pbs-5), which are essential for oxidative stress tolerance 
 45 
 
 
in C. elegans (122). However, it is not clear if chicoric acid regulates SKN-1 directly or 
by regulating upstream regulators of SKN-1. In fact, AAK-2 was suggested to be the 
upstream of SKN-1 for metformin-mediated lifespan extension in a previous publication 
(96). Moreover, another study suggested that glycogen synthase kinase-3 (GSK-3) is the 
upstream of SKN-1 contributing to the increased resistance of oxidative stress in C. 
elegans (128). Thus, future experiments are needed to determine the target of chicoric 
acid on enhanced oxidative stress resistance.  
Moreover, both AAK-2 and SKN-1 have been reported to regulate mitochondrial 
biogenesis against oxidative stress and contribute to longevity in C. elegans, suggesting 
the possible effect of chicoric acid on mitochondrial function (98, 129). One study 
reported that chicoric acid promotes mitochondrial biogenesis by increasing citrate 
synthase activity and the deacetylation of peroxisome proliferator-activated receptor-γ 
coactivator, which is directly activated by AMPKα (7). Thus, we cannot exclude the 
possibility that chicoric acid extends lifespan via a mitochondrial biogenesis-mediated 
mechanism.   
Chicoric acid is metabolized to 2-caffeoyl-L-tartaric acid (cafraric acid) and 
caffeic acid by rat liver microsomes (76). A recent study reported that chicoric acid has 
low absorption in rats, with peak plasma concentration at 3.44±0.53 µM after 4 h of oral 
administration of chicoric acid at 50 mg/kg body weight (91). Thus, the 25 µM of 
chicoric acid used in the current study might be difficult to achieve in animals and 
humans. Moreover, currently the comparability of chicoric plasma concentration between 
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C. elegans and other in vivo models is not known; thus, it is important to determine the 
biological relevance of chicoric acid in humans.    
In conclusion, chicoric acid significantly extended the lifespan of C. elegans in 
part through regulation of aak-2 and skn-1. Because of the high conservation of these two 
genes between nematodes and mammals, these findings indicate that chicoric acid may 
have potential for promoting healthy aging as well as combatting age-related diseases in 
humans.  
 
 
 
Fig. 4.8 The graphic contents. Chicoric acid significantly extended the lifespan of C. 
elegans and increase the oxidative stress resistance in part through regulation of aak-2 
and skn-1.   
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4.2 Effect of chicoric acid on glucose uptake and the underlying mechanism 
4.2.1 Introduction 
Type 2 diabetes mellitus (T2DM) has been recognized as a major public health 
challenge throughout the world in recent decades (8, 9). Impaired glucose uptake in 
muscle tissues is the primary associated with hyperglycemia in T2DM (10). Upon insulin 
signaling, protein kinase B, also known as Akt, is activated by phosphorylation that leads 
to translocation of glucose transporter 4 (GLUT4) to the plasma membrane, which 
subsequently promotes glucose uptake (126, 130-132). In addition to insulin signaling, 
several studies indicated that AMP-activated protein kinase α (AMPKα), which is known 
to regulate energy homeostasis (133, 134), also activates Akt, independent of insulin, and 
results in increased glucose uptake (135, 136).  
Accumulating evidence suggests that many natural bioactive components have 
great potential to be used for the prevention or amelioration of T2DM (126, 137). Among 
natural bioactives, chicoric acid has been recently reported to have potential anti-diabetic 
effects (11, 51, 73). It is a naturally occurring dicaffeoyl ester often found in chicory 
plants and basil (Fig. 1A) (138, 139). One study reported that chicoric acid promoted 
glucose uptake in L6 muscle cells (11). More recently, another study revealed that 
chicoric acid regulated glucose homeostasis, stimulated the AMPKα pathway, and 
reversed insulin resistance in HepG2 cells (52). However, it is still not clear whether 
chicoric acid enhances glucose uptake in muscle cells via an AMPKα-mediated pathway. 
A better understanding of chicoric acid’s impact in promoting glucose uptake in muscle 
cells would be significant given that muscle is responsible for approximately 75% of 
glucose disposal in the body (140). We used C2C12 myotubes, derived from murine 
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skeletal muscle cells and a C57BL/6J mice model to determine the role of chicoric acid 
on glucose homeostasis and its underlying mechanisms (141, 142).  
 
4.2.2 Materials and methods 
4.2.2.1 Materials 
Chicoric acid (≥ 98%) was obtained from Santa Cruz Biotechnology, Inc. (Santa 
Cruz, CA, USA). C2C12 murine skeletal myoblasts were from American Type Cell 
Collection (Manassas, VA, USA). Bovine serum albumin, recombinant human insulin, 
and a penicillin/streptomycin mixture were purchased from Thermo Fisher (Waltham, 
MA, USA). Dulbecco’s Modified Eagle’s Medium (DMEM), Kaighn’s Modification of 
Ham’s F-12 (F-12K), fetal bovine serum (FBS), dimethyl sulfoxide (DMSO), 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT, purity ≥ 93%), and horse 
serum (HS) were obtained from Sigma-Aldrich (St. Louis, MO, USA). Dorsomorphin 
dihydrochloride (purity≥98%), also named Compound C, was purchased from MedChem 
Express (Monmouth Junction, NJ, USA). The protein content was determined using 
protein DC assay kits from Bio-Rad Co. (Hercules, CA, USA). Rabbit antibodies for 
phospho-Akt (Ser473), Akt (total), phospho-AMPKα, AMPKα (total), phospho-acetyl-
CoA carboxylase (ACC) (Ser79), ACC (total), mouse antibody for GLUT4, goat anti-
rabbit IgG-horseradish peroxidase (HRP), and goat anti-mouse IgG-HRP were obtained 
from Cell Signaling Technology (Danvers, MA, USA). Rabbit antibodies for β-actin and 
Na+/K+-ATPase were purchased from Santa Cruz Biotechnology, Inc (Dallas, TX, USA).  
 
4.2.2.2 C2C12 culture 
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C2C12 cells were cultured in a 5% CO2 atmosphere at 37°C. Myoblasts were 
cultured and differentiated into multinucleated myotubes based on previous studies (143). 
After 6 days of differentiation, myotubes were treated with chicoric acid (12.5, 25, and 50 
µM) for 24 h. For insulin treatment, 100 nM insulin was added into media for 30 min 
before the harvest of cells. A previous study reported that 20 µM Compound C inhibited 
the activity of AMPKα in primary hepatocytes (144). In the current model, 10 µM 
Compound C was able to inhibit AMPKα phosphorylation in C2C12 cells. Thus, 10 µM 
Compound C was used in this study. An MTT-based cell viability test was used to 
determine the cytotoxicity of chicoric acid (145). Briefly, C2C12 myoblasts were seeded 
in 96-well plates at a density of 1 × 106 cells/mL. Cells were treated with 12.5, 25, and 50 
μM of chicoric acid for 24 h. The medium was then replaced with 5 mg/mL MTT in 
DMEM (without phenol red) for 4 h at 37°C. After incubation, cells were washed thrice 
with phosphate-buffered saline (PBS) and formazan crystals dissolved in DMSO were 
measured with microplate reader SpectraMax i3 (Sunnyvale, CA, USA) at 570 nm. 
Concentrations of chicoric acid tested (0-50 µM) were not toxic to C2C12 cells as shown 
in Fig. 4.9A.  
 
4.2.2.3 Glucose uptake assay 
For glucose uptake measurement, 2-(N-(7-nitrobenz-2-oxa-1,3-diazol-4-
yl)amino)-2-deoxyglucose (2-NBDG), a fluorescent derivative of glucose, was used as 
described previously (143). Myoblasts were seeded in the 24-well plates. After 6 days of 
differentiation, myotubes were treated with various doses of chicoric acid in F-12K (5.5 
mM glucose) serum free media for different time periods as shown the Figure legends. 
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C2C12 myotubes were then treated with and without 100 nM insulin for 30 min in a 
Krebs-Ringer buffer that was prepared as published previously (146). Insulin (30 min) 
stimulation was used to activate insulin signaling in C2C12 myotubes as previously 
described (147, 148). After insulin stimulation, the 2-NBDG solution was added to each 
well at a final concentration of 200 µM, and the cells were incubated at 37 °C for 30 min. 
Cells were then rinsed thrice with ice cold PBS and the fluorescence was immediately 
measured using the SpectraMax i3 microplate reader at excitation/emission 465/540 nm. 
The cell lysate was prepared by adding 40 µl 0.1 M NaOH per well. The protein content 
of each well was determined by protein DC assay kits. The fluorescence was normalized 
by protein content.  
 
4.2.2.4 Cell membrane protein extraction 
Integral membrane proteins and membrane-related proteins from C2C12 
myotubes were prepared using a Mem-PER Plus Membrane Protein Extraction Kit from 
Thermo Fisher Scientific (Waltham, MA, USA) according to the manufacturer’s 
instructions. GLUT4 translocated to membrane and total GLUT4 were determined by 
immunoblotting.  
 
4.2.2.5 Transfection of shRNA-AMPKα 
Lentivirus-mediated short hairpin RNA (shRNA) targeting of the mouse 
AMPKα1 gene (shAMPKα) was established by Shanghai R&S Biotechnology Co. Ltd 
(Shanghai, China). Detailed information is provided in supplementary data 
(Supplementary Table S1 and Figure S2). The effective target sequence 
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ACGAGTTGACCGGACATAAAA in the mouse AMPKα1 gene (GeneID: 
NM_001013367.3) was selected, and a scrambled sequence: 
GAAATGTACTGCGCGTGGAGACGTTTTGGCCACTGACTGACGTCTCCACGCA
GTACATTT that had no significant homology to any mouse gene sequences was used as 
a negative control (shControl). Transfection of shRNA was performed based on the 
manufacturer’s instructions. A virus counted with approximately 100 multiplicity of 
infection (MOI) was used to infect one well of cells in a 6-well plate for 12 h in a serum-
free medium with polybrene (8 µg/mL), and the cell culture medium was then changed to 
a normal medium containing 10% FBS. After 48 h incubation, cells were treated with 
chicoric acid (0 or 25 µM) for 24 h. AMPKα protein levels were measured by Western 
blotting.  
 
4.2.2.6 Western blotting 
C2C12 cell lysate was prepared for immunoblotting as described previously (107, 
148). Protein concentrations were determined by the protein DC assay kits. β-Actin was 
used as an internal control. Horseradish peroxidase-conjugated goat anti-rabbit IgG was 
used as the secondary antibody. Protein blots were pictured by the Image Station 
4000MM (Carestream Health, New Haven, CT, USA) with a Clarity Western ECL 
Substrate Kit (Bio-Rad Co.). Images were quantified with ImageJ software (version 1.49, 
National Institutes of Health, MD, USA).  
 
4.2.2.7 AMP/ATP assay 
The measurement of AMP and ATP from C2C12 myotubes was conducted using 
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a mouse AMP/ATP ELISA kit (Shanghai Fan Ke Biotechnology Co., Ltd., Shanghai, 
China). Briefly, C2C12 cells were treated with chicoric acid (25 µM) for 24 h, followed 
by washing with cold PBS twice at 4°C. Then cells were diluted by PBS to reach the final 
concentration 1 x 107 cells/ml. The diluted cells were lysed with a lysis buffer according 
to the manufacturer’s instructions. The supernatant was obtained by centrifugation for 20 
min at the speed of 3000 rpm. Then the supernatant of cell lysate was taken to detect the 
levels of AMP and ATP following the protocol of the ELISA kit. The absorbance of each 
sample was read by the Multiskan FC microplate reader (Thermo Fisher Scientific, 
Waltham, MA, USA) at 450nm after adding a stop solution for 15 min. 
 
4.2.2.8 Glucose tolerance test (GTT) 
Male C57BL/6J mice (8 week) were obtained from the Laboratory Animal 
Research Center of Jiangsu University (Jiangsu, China) and maintained on a 12 h 
light/dark cycle with free access to food and water for 2 weeks. Institutional guidelines 
(serial No. UJS-LAER-2018042301) for animal care and use were followed, and the 
animal protocol was approved by the animal ethics committee of Jiangsu University. 
After adaptation, the mice were divided into two groups (6-8 mice/group).  For the 
treatment groups, mice received a daily oral administration of 5 mg/kg BW chicoric acid 
for 5 days, based on a previous publication (59). For the control group, mice will be 
administrated with saline solution orally. Mice body weight will be measured before 
glucose tolerance test (GTT). On the fifth day, all mice will be fasted for 12 h following 
the first measurement of blood glucose from the tail vein by a blood glucose meter (0 min, 
ACCU-CHEK, Jiangsu, China). Then, all mice will be subjected to an intraperitoneal 
 53 
 
 
GTT (2 g glucose/kg BW). The blood glucose levels will be further monitored at 15, 30, 
60, and 120 min. The areas under the curves (AUCs) were calculated with Sigma Plot 
(version 11.0, Systat Software, Inc, San Jose, CA, USA). 
 
4.2.2.9 Statistical analysis 
SAS software (version 9.3, SAS Institute Inc., Cary, NC, USA) was used for 
statistical analysis. One-way analysis of variance (ANOVA) was used for all data except 
for Fig. 4.9B, Fig. 4.10A, Fig. 4.11B, Fig. 4.13, and Fig. 4.14, where two-way ANOVA 
with least squares means statement was used. When there were no interactions between 
chicoric acid and another factor (insulin or time), no letter was used in the figures. If 
there were significant interactions between chicoric acid and another factor (Compound 
C or shAMPK), letters were used in the figures to present the differences between each 
group. The Tukey−Kramer method was applied for the multiple comparisons among the 
groups. A difference was considered significant at P<0.05.   
 
4.2.3 Results  
4.2.3.1  Chicoric acid promoted glucose uptake 
When overall glucose uptake was measured by using 2-NBDG from C2C12 
myotubes, there were significant effects of insulin (P=0.0006) and chicoric acid (P< 
0.0001) without any significant interaction between insulin and chicoric acid (Fig. 4.9A). 
Glucose uptake in insulin-stimulated groups was 20%-25% higher than in non-insulin-
stimulated groups. This is consistent with previous reports that less than 30% increase of 
glucose uptake after insulin stimulation with 2-NBDG (149, 150). The exposure of 
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C2C12 cells to chicoric acid at the concentrations of 25 and 50 µM resulted in significant 
increases in glucose uptake regardless of insulin stimulation compared to the controls (P= 
0.001 and P=0.009, respectively, Fig. 4.9B). The effect of increased glucose uptake by 
chicoric acid (25 µM) peaked after a 24 h treatment, and was significantly 36% greater 
than the control group (P<0.0001; Fig. 4.9C); thus, a 24 h chicoric acid treatment was 
used for the subsequent experiments. 
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Figure 4.9 Chicoric acid promoted glucose uptake in C2C12 myotubes. (A) 
Concentrations of chicoric acid tested (0-50 µM) were not toxic to C2C12 cells. (B) 
Glucose uptake was measured from myotubes that were treated with chicoric acid (12.5, 
25 or 50 µM) for 24 h, followed by a 30-min treatment with or without 100 nM of insulin. 
(C) Myotubes were treated with 25 µM chicoric acid for 12 h, 24 h or 48 h in F-12K (5.5 
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mM glucose) serum free media, respectively. Since glucose uptake was induced by 
chicoric acid independent of insulin, no insulin stimulation was conducted in this test. 
After washing thrice, 2-NBDG solution was added to each well at a final concentration of 
200 µM, and the cells were incubated at 37 °C for 30 min. Cells were then rinsed thrice 
with ice cold PBS and the fluorescence was immediately measured using the SpectraMax 
i3 microplate reader at excitation/emission 465/540 nm. Numbers are mean ± S.E. (n=5). 
Means with different letters are significantly different at P<0.05.  
 
We also conducted in vivo glucose tolerance tests (GTT) to determine if chicoric 
acid supplementation would have the similar results. There were significant effects in 
GTT for time (P< 0.0001) and chicoric acid (P< 0.0001) without any significant 
interaction between time and chicoric acid (Fig. 4.10A). Chicoric acid treatment (5 mg/kg 
BW for 5 days) led to a 14.5% reduction of the overall blood glucose level compared to 
the control (P< 0.0001; Fig. 2A). The areas under the curves (AUCs) in GTT further 
confirms that chicoric acid treatments improved glucose tolerance in mice (P= 0.0065, 
Fig. 4.10B). 
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Fig. 4.10 Effects of chicoric acid on glucose tolerance test (GTT). Mice were 
administrated with (0 and 5 mg/kg BW/day) chicoric acid orally for 5 days. (A) Blood 
was collected from the tail vein, and glucose levels were measured at 0 min, then the 
glucose solution (2 g/kg BW) was administered by intraperitoneal injection and blood 
glucose level were determined at 15, 30, 60 and 120 min. (B) Area under the curve 
(AUC). Values are means ± S.E. (n = 6), **P<0.01. Means with different letters are 
significantly different at P< 0.05. 
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4.2.3.2 Effects of chicoric acid on Akt activation and GLUT4 translocation in C2C12 
myotubes  
It is known that the activation of Akt (phosphorylated-Akt, p-Akt) and GLUT4 
translocation to the plasma membrane directly regulate glucose uptake in muscle cells (9, 
131). Thus, we examined the effects of chicoric acid on the phosphorylation of Akt and 
GLUT4 translocation from C2C12 myotubes. Fig. 4.11A and 4.11B show that the ratio of 
p-Akt/Akt (as an indicator of activation of Akt) was significantly increased by insulin 
(P<0.0001) and chicoric acid (P=0.0003), without any interaction between insulin and 
chicoric acid. These results are consistent with the results in Fig. 4.9A that chicoric acid 
promoted glucose uptake in an insulin-independent manner. From these results, we 
selected 25 µM chicoric acid to determine its effect on GLUT4 translocation since this 
concentration had the highest activation of Akt, a 132% increase over the control in this 
model (P<0.0001; Fig. 4.11A). As shown in Fig 4.11C-E, the treatment of 25 µM 
chicoric acid resulted in a 28% increase in GLUT4 translocation to the cell membrane 
compared to the control (P=0.0086) without altering total GLUT4 expression. These 
results suggest that chicoric acid activated Akt independently of insulin and promoted 
GLUT4 translocation to the plasma membrane. 
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Figure 4.11 Activation of Akt and translocation of glucose transporter 4 (GLUT4) by 
chicoric acid in C2C12 myotubes. (A) Myotubes were treated with the indicated 
concentrations of chicoric acid for 24 h and/or 100 nM insulin for 30 min in F-12K 
serum-free medium. Then phosphorylation of Akt and total Akt was determined by 
immunoblotting. (B) p-Akt/Akt, phosphorylated protein kinase B/protein kinase B. (C) 
Chicoric acid induced translocation of GLUT4. C2C12 myotubes were treated with 25 
µM of chicoric acid for 24 h. Then the protein of plasma membrane and whole cells were 
extracted to immunoblotting. (D) Mem-GLUT4/ Na+/K+-ATPase, GLUT4 on cell 
membrane/internal reference on cell membrane. (E) Total GLUT4/β-actin, GLUT4 in 
whole cells/internal reference in whole cells. Numbers are mean ± S.E. (n=3), **P<0.01. 
Means with different letters are significantly different at P< 0.05. 
 
4.2.3.3 Effects of chicoric acid on the AMPKα signaling pathway in C2C12 
myotubes 
Based on previous reports that chicoric acid promoted AMPKα activation in L6 
myocytes (73), and AMPKα can activate Akt (135, 136), we determine if the effect of 
chicoric acid (12.5 and 25 µM) on Akt was dependent upon AMPKα (Fig. 4.12). First, 
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we have confirmed that chicoric acid (25 µM) activated AMPKα (the ratio of p-
AMPKα/AMPKα) with a 131% increase over the control (Fig. 4.12B). It was further 
confirmed that phosphorylation of ACC/ACC, one of main downstream targets of 
AMPKα, was consistently increased by chicoric acid treatment (Fig. 4.12C).  
 
Figure 4.12 Activation of AMP-activated protein kinase α (AMPKα) pathway by 
chicoric acid in C2C12 myotubes. (A) Myotubes were treated with chicoric acid (12.5 
µM or 25 µM) for 24 h in DMEM. Phosphorylation of AMPKα and ACC and the total 
were determined by immunoblotting. (B) p-AMPKα/AMPKα, phosphorylated AMP-
activated protein kinase-α/AMP-activated protein kinase-α. (C) p-ACC/ACC, 
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phosphorylated acetyl-CoA carboxylase/acetyl-CoA carboxylase. Numbers are mean ± 
S.E. (n=4). Means with different letters are significantly different at P<0.05. 
 
Next, we further proved that activation of AMPKα is involved in the effects of 
chicoric acid on activation of Akt by using two approaches: an AMPKα inhibitor 
(Compound C) and AMPKα knockdown cells. Compound C was regarded as a selective 
AMPKα inhibitor with no influence on kinases that have similar structures with AMPKα 
(144). Therefore, we used Compound C first to determine whether Akt activation by 
chicoric acid is mediated by an AMPKα-dependent pathway (144). Both Compound C 
and chicoric acid had significant effects on Akt phosphorylation, with a significant 
interaction between Compound C and chicoric acid (P= 0.049). The phosphorylation of 
AMPKα by chicoric acid was inhibited after treatment with Compound C (10 µM) as 
expected (Fig 4.13A-B). Chicoric acid consistently upregulated Akt phosphorylation 
without Compound C (P= 0.003), while chicoric acid induced Akt activation was 
abolished by Compound C (Fig. 4.13A & C). 
 62 
 
 
 
Figure 4.13 Increased glucose uptake and activation of Akt by chicoric acid were 
abolished by the inhibition of AMPKα. (A) Cells were treated with 10 µM compound C 
for 12 h, then myotubes were treated with 25 µM chicoric acid for 24h. (B) p-
AMPKα/AMPKα, phosphorylated AMP-activated protein kinase-α/AMP-activated 
protein kinase-α. (C) p-Akt/Akt, phosphorylated protein kinase B/protein kinase B. 
Numbers are mean ± S.E. (n=3-5). Means with different letters are significantly different 
at P<0.05. 
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Next, we prepared AMPKα knockout cells to further confirm if chicoric acid had 
significant effects on Akt phosphorylation and glucose uptake. As shown in Fig. 4.14A 
and B, knocking-out AMPKα abolished the effects of chicoric acid on the activation of 
Akt. Consistently, increased glucose uptake by chicoric acid was abolished in AMPKα 
knock-out cells (Fig. 4.14C). These results indicate that chicoric acid increases the 
phosphorylation of Akt and glucose uptake through an AMPKα-dependent pathway.  
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Figure 4.14 Increased glucose uptake and activation of Akt by chicoric acid were 
abolished by shAMPKα. (A) Cells were infected with lentivirus vectors expressing 
shRNA targeting mouse AMPKα1. Phosphorylation of Akt and the total Akt were 
determined by immunoblotting. (B) p-Akt/Akt, phosphorylated protein kinase B/ protein 
kinase B. (C) Glucose levels were determined in C2C12 myotubes treated with 0 or 25 
µM chicoric acid for 24 h. Numbers are mean ± S.E. (n=3-5). Means with different letters 
are significantly different at P<0.05. 
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In aerobic respiration, an increase in AMP level has been reported to directly 
induce AMPKα activation (151). Thus, we further determined if AMPKα activation by 
chicoric acid is attributed to the enhanced AMP/ATP ratio. Figure 4.15 showed that the 
AMP/ATP ratio was increased by 133% in the 25 µM chicoric acid treatment group 
compared with the control (P<0.001), which suggests that chicoric acid activates AMPKα 
via regulation of the AMP/ATP ratio. 
 
Figure 4.15 Chicoric acid enhanced AMP/ATP ratio in C2C12 myotubes. After 24 h of 
chicoric acid treatment, cells were lysed, and the supernatant lysate was taken to detect 
the levels of AMP and ATP using a commercial kit. The absorbance of each sample was 
determined by after incubation for 15 min. Values are means ± S.E. (n =3), ***P<0.001. 
 
4.2.4 Discussion 
Several phenolic secondary metabolites, such as chlorogenic acid and caffeic acid, 
have been used as antihyperglycemic compounds in pharmaceutical formulations (11, 
137). Chicoric acid, a new phenolic ester, has been reported to have a beneficial effect on 
glucose transport in several studies (51, 52, 59, 73). Consistently, we demonstrated that 
chicoric acid increased glucose uptake and activated Akt, particularly at 25 µM, and these 
effects were dependent to AMPKα, but not insulin, in C2C12 myotubes. The 
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hypoglycemic effects of chicoric acid were further confirmed in vivo using mice at 5 mg 
chicoric acid/kg BW. 
One in vivo study showed that chicoric acid (3 mg/kg BW) decreased the blood 
glucose level by 53% with a 120 min treatment in diabetic mice (59). Others reported that 
the extract from Cichorium intybus root, containing about 15 or 30 mg chicoric acid/kg 
BW, significantly decreased blood glucose level after 4 days in male Wistar rats (152). 
This is consistent with the current study which found that chicoric acid can significantly 
reduce glucose levels in male mice. Zhu et al. (51) reported that chicoric acid ameliorated 
glucosamine-induced insulin resistance through enhanced glucose uptake in HepG2 cells. 
Our current results indicate that chicoric acid increased glucose uptake, independent of 
insulin, in C2C12 myotubes (51, 149, 153). However, the current results are inconsistent 
with Tousch et al. (11), who found chicoric acid to increase glucose uptake only with 
insulin stimulation in L6 skeletal muscle cells . The inconsistency between the current 
results and that of Tousch et al. might be due to the different statistical analysis methods 
used for the latter (i.e. one-way, vs. two-way ANOVA in the current study). Alternatively, 
the inconsistency may derive from: using different cell lines (mice vs. rat muscle cell 
lines); different determination methods for glucose uptake; or a different length of 
treatment time (2-NBDG with 24 h treatment in the current study vs. [3H] deoxyglucose 
with 1 h treatment in Tousch et al.).  
AMPKα is a master regulator of energy homeostasis by activating proteins in 
catabolism pathways while turning off biosynthetic pathways (154). In cellular 
respiration, an increase in AMP level relative to ATP activates AMPKα, which further 
stimulates the acute upregulation of ATP production and the downregulation of non-
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essential energy expenditure (155). Previous evidence also suggests that AMPKα is an 
important regulator of glucose transport, especially in muscle tissue by phosphorylation 
of insulin receptors, independent of insulin (135). Moreover, chicoric acid was previously 
reported to activate AMPKα, which was suggested to be involved in the regulation of 
glucose metabolism in HepG2 cells (52). In our study, a different cell line (C2C12 
myotubes) was used, and we further found that chicoric acid increased the cellular 
AMP/ATP ratio, which might contribute to AMPKα activation. Prior study has suggested 
that increased cellular AMP level may attributed to an increase in mitochondrial 
respiration without a corresponding increase in ATP synthesis by oxidative 
phosphorylation, a process described as uncoupling of oxidative phosphorylation (156). It 
was reported that some caffeic acid phenethyl esters (CAPEs), the derivatives of caffeic 
acid, activated AMPKα through uncoupling of oxidative phosphorylation-induced 
increase in AMP level (156, 157). Since chicoric acid is structurally similar to CAPEs, 
we speculate that the increased AMP/ATP ratio by chicoric acid may from a mechanism 
similar to that of CAPEs. However, this still needs to be determined in future study.  
Along with its hypoglycemic effect, there are reports of chicoric acid having other 
functional properties, such as antioxidation, anti-inflammation, and anti-fatty liver 
activities (63, 84). Chicoric acid has been considered a potent antioxidant agent due to its 
effect on inhibiting the accumulation of reactive oxygen species and the generation of 
inflammatory cytokines, such as nitrogen oxide, interleukin 6, and tumor necrosis factor-
α (51, 64). Others have reported that chicoric acid promotes mitochondrial biogenesis by 
enhancing the citrate synthase activity and the deacetylation of peroxisome proliferator-
activated receptor-γ coactivator, which is directly activated by AMPKα (73, 154). More 
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information about such properties will help us better understand chicoric acid as a 
functional food bioactive.  
In conclusion, chicoric acid promoted insulin-independent glucose uptake and Akt 
phosphorylation by post-translational regulation of AMPKα in C2C12 myotubes, and 
improved glucose tolerance in the mice model. The current study demonstrated that 
chicoric acid is a potential antidiabetic nutraceutical that may be used for the prevention 
or treatment of diabetes.  
 
 
Fig. 4.16 The graphic contents. Chicoric acid promoted insulin-independent glucose 
uptake and Akt phosphorylation by post-translational regulation of AMPKα in C2C12 
myotubes.    
 69 
 
 
BIBLIOGRAPHY 
1. Lee, J.; Scagel, C. F., Chicoric acid: chemistry, distribution, and production. 
Front. Chem. 2013, 31, 40. 
2. Bauer, R., Chemistry, analysis and immunological investigations of Echinacea 
phytopharmaceuticals. In Immunomodulatory agents from plants, Springer: 1999; pp 41-
88. 
3. Birt, D. F.; Widrlechner, M. P.; LaLone, C. A.; Wu, L.; Bae, J.; Solco, A. K. S.; 
Kraus, G. A.; Murphy, P. A.; Wurtele, E. S.; Leng, Q.; Hebert, S. C.; Maury, W. J.; Price, 
J. P., Echinacea in infection. Am. J. Clin. Nutr. 2008, 87, 488-492. 
4. Zhang, Y.; Tang, T.; He, H.; Wu, H.; Hu, Z., Influence of several postharvest 
processing methods on polyphenol oxidase activity and cichoric acid content of 
Echinacea purpurea roots. Ind. Crop Prod. 2011, 34, 873-881. 
5. Harman, D., The free radical theory of aging. Antioxid. Redox Signal. 2003, 5, 
557-561. 
6. Niccoli, T.; Partridge, L., Ageing as a risk factor for disease. Curr. Biol. 2012, 22, 
741-752. 
7. Schlernitzauer, A.; Oiry, C.; Hamad, R.; Galas, S.; Cortade, F.; Chabi, B.; Casas, 
F.; Pessemesse, L.; Fouret, G.; Feillet-Coudray, C.; Cros, G.; Cabello, G.; Magous, R.; 
Wrutniak-Cabello, C., Chicoric acid is an antioxidant molecule that stimulates AMP 
kinase pathway in L6 myotubes and extends lifespan in Caenorhabditis elegans. PloS 
one 2013, 8, e78788. 
8. Copeland, K. C.; Silverstein, J.; Moore, K. R.; Prazar, G. E.; Raymer, T.; 
Shiffman, R. N.; Springer, S. C.; Thaker, V. V.; Anderson, M.; Spann, S. J., Management 
of newly diagnosed type 2 diabetes mellitus (T2DM) in children and adolescents. 
Pediatrics 2013, 131, 364-382. 
9. Donath, M. Y.; Shoelson, S. E., Type 2 diabetes as an inflammatory disease. Nat. 
Rev. Immunol. 2011, 11, 98-107. 
10. Saltiel, A. R., New perspectives into the molecular pathogenesis and treatment of 
type 2 diabetes. Cell 2001, 104, 517–529. 
11. Tousch, D.; Lajoix, A. D.; Hosy, E.; Azay-Milhau, J.; Ferrare, K.; Jahannault, C.; 
Cros, G.; Petit, P., Chicoric acid, a new compound able to enhance insulin release and 
glucose uptake. Biochemical and Biophysical Research Communications 2008, 377, 131-
135. 
 70 
 
 
12. Bais, H. P.; Ravishankar, G. A., Cichorium intybus L–cultivation, processing, 
utility, value addition and biotechnology, with an emphasis on current status and future 
prospects. J. Sci. Food Agric. 2001, 81, 467-484. 
13. Street, R. A.; Sidana, J.; Prinsloo, G., Cichorium intybus: traditional uses, 
phytochemistry, pharmacology, and toxicology. Evid. Based Complement. Alternat. Med. 
2013, 2013, 1-13. 
14. Nandagopal, S.; Kumari, B. R., Phytochemical and antibacterial studies of 
Chicory (Cichorium intybus L.)-A multipurpose medicinal plant. Adv. Biol. Res. 2007, 1, 
17-21. 
15. Barrett, B., Medicinal properties of Echinacea: A critical review. Phytomedicine 
2003, 10, 66-86. 
16. Robinson, W. E.; Reinecke, M. G.; AbdelMalek, S.; Jia, Q.; Chow, S. A., 
Inhibitors of HIV-1 replication that inhibit HPV integrase. Proc. Natl. Acad. Sci. U. S. A. 
1996, 93, 6326-6331. 
17. Beale, K. K.; Robinson, E. W., Combinations of reverse transcriptase, protease, 
and integrase inhibitors can be synergistic in vitro against drug-sensitive and RT 
inhibitor-resistant molecular clones of HIV-1. Antivir. Res. 2000, 46, 223-232. 
18. Crosby, D. C.; Lei, X. Y.; Gibbs, C. G.; McDougall, B. R.; Robinson, W. E.; 
Reinecke, M. G., Design, synthesis, and biological evaluation of novel hybrid 
dicaffeoyltartaric/diketo acid and tetrazole-substituted l-chicoric acid analogue inhibitors 
of human immunodeficiency virus type 1 Integrase. J. Med. Chem. 2010, 53, 8161-8175. 
19. King, P. J.; Ma, G. X.; Miao, W. F.; Jia, Q.; McDougall, B. R.; Reinecke, M. G.; 
Cornell, C.; Kuan, J.; Kim, T. R.; Robinson, W. E., Structure-activity relationships: 
Analogues of the dicaffeoylquinic and dicaffeoyltartaric acids as potent inhibitors of 
human immunodeficiency virus type 1 integrase and replication. J. Med. Chem. 1999, 42, 
497-509. 
20. King, P. J.; Robinson, W. E., Resistance to the anti-human immunodeficiency 
virus type 1 compound L-chicoric acid results from a single mutation at amino acid 140 
of integrase. J. Virol. 1998, 72, 8420-8424. 
21. Reinke, R. A.; King, P. J.; Victoria, J. G.; McDougall, B. R.; Ma, G. X.; Mao, Y. 
Q.; Reinecke, M. G.; Robinson, W. E., Dicaffeoyltartaric acid analogues inhibit human 
immunodeficiency virus type 1 (HIV-1) integrase and HIV-1 replication at nontoxic 
concentrations. J. Med. Chem. 2002, 45, 3669-3683. 
22. Reinke, R. A.; Lee, D. J.; McDougall, B. R.; King, P. J.; Victoria, J.; Mao, Y. Q.; 
Lei, X. Y.; Reinecke, M. G.; Robinson, W. E., L-chicoric acid inhibits human 
 71 
 
 
immunodeficiency virus type 1 integration in vivo and is a noncompetitive but reversible 
inhibitor of HIV-1 integrase in vitro. Virology 2004, 326, 203-219. 
23. Robinson, W. E., L-chicoric acid, an inhibitor of human immunodeficiency virus 
type 1 (HIV-1) integrase, improves on the in vitro anti-HIV-l effect of Zidovudine plus a 
protease inhibitor (AG1350). Antivir. Res. 1998, 39, 101-111. 
24. Chiu, T. K.; Davies, D. R., Structure and function of HIV-1 integrase. Curr. Top. 
Med. Chem. 2004, 4, 965-977. 
25. Hu, J. P.; Chang, S.; Chen, W. Z.; Wang, C. X., Study on the drug resistance and 
the binding mode of HIV-1 integrase with LCA inhibitor. Sci. China Ser. B 2007, 50, 
665-674. 
26. King, P. J.; Lee, D. J.; Reinke, R. A.; Victoria, J. G.; Beale, K.; Robinson, W. E., 
Human immunodeficiency virus type-1 integrase containing a glycine to serine mutation 
at position 140 is attenuated for catalysis and resistant to integrase inhibitors. Virology 
2003, 306, 147-161. 
27. Healy, E. F.; Sanders, J.; King, P. J.; Robinson, W. E., A docking study of L-
chicoric acid with HIV-1 integrase. J. Mol. Graph. Model. 2009, 27, 584-589. 
28. Sahu, K. K.; Ravichandran, V.; Jain, P. K.; Sharma, S.; Mourya, V. K.; Agrawal, 
R. K., QSAR analysis of chicoric acid derivatives as HIV-1 integrase inhibitors. Acta. 
Chim. Slov. 2008, 55, 138-145. 
29. McDougall, B.; King, P. J.; Wu, B. W.; Hostomsky, Z.; Reinecke, M. G.; 
Robinson, W. E., Jr., Dicaffeoylquinic and dicaffeoyltartaric acids are selective inhibitors 
of human immunodeficiency virus type 1 integrase. Antimicrob Agents Chemother 1998, 
42, 140-146. 
30. Charvat, T. T.; Lee, D. J.; Robinson, W. E.; Chamberlin, A. R., Design, synthesis, 
and biological evaluation of chicoric acid analogs as inhibitors of HIV-1 integrase. 
Bioorganic Med. Chem. 2006, 14, 4552-4567. 
31. Meadows, D. C.; Mathews, T. B.; North, T. W.; Hadd, M. J.; Kuo, C. L.; Neamati, 
N.; Gervay-Hague, J., Synthesis and biological evaluation of geminal disulfones as HIV-
1 integrase inhibitors. J. Med. Chem. 2005, 48, 4526-4534. 
32. Meadows, D. C.; Sanchez, T.; Neamati, N.; North, T. W.; Gervay-Hague, J., Ring 
substituent effects on biological activity of vinyl sulfones as inhibitors of HIV-1. 
Bioorganic Med. Chem. 2007, 15, 1127-1137. 
33. Liu, Q.; Chen, Y. W.; Shen, C.; Xiao, Y. T.; Wang, Y. T.; Liu, Z. G.; Liu, X. B., 
Chicoric acid supplementation prevents systemic inflammation- induced memory 
 72 
 
 
impairment and amyloidogenesis via inhibition of NF-kappa B. Faseb J. 2017, 31, 1494-
1507. 
34. Liu, Q.; Hu, Y. Y.; Cao, Y. F.; Song, G.; Liu, Z. G.; Liu, X. B., Chicoric acid 
ameliorates lipopolysaccharide-lnduced oxidative stress via promoting the Keapl/Nrf2 
transcriptional signaling pathway in BV-2 Microglial cells and mouse brain. J. Agric. 
Food Chem. 2017, 65, 338-347. 
35. Matthias, A.; Banbury, L.; Stevenson, L. M.; Bone, K. M.; Leach, D. N.; 
Lehmann, R. P., Alkylamides from Echinacea modulate induced immune responses in 
macrophages. Immunol. Invest. 2007, 36, 117-130. 
36. Stevenson, L. M.; Matthias, A.; Banbury, L.; Penman, K. G.; Bone, K. M.; Leach, 
D. L.; Lehmann, R. P., Modulation of macrophage immune responses by Echinacea. 
Molecules 2005, 10, 1279-1285. 
37. Brasier, A. R., The NF-κB regulatory network. Cardiovasc. Toxicol. 2006, 6, 111-
130. 
38. Gilmore, T. D., Introduction to NF-κB: players, pathways, perspectives. 
Oncogene 2006, 25, 6680. 
39. Zheng, X. X.; Maslinski, W.; Ferrari-Lacraz, S.; Strom, T. B., Cytokines in the 
Treatment and Prevention of Autoimmune Responses. 2013. 
40. Jiang, L.; Li, W. Z.; Wang, Y. C.; Zhang, X. S.; Yu, D. Q.; Yin, Y. Y.; Xie, Z. W.; 
Yuan, Y., Effects of cichoric acid extract from Echinacea purpurea on collagen-induced 
arthritis in rats. Am. J.  Chinese Med. 2014, 42, 679-692. 
41. Kour, K.; Bani, S.; Sangwan, P. L.; Singh, A., Upregulation of Th1 polarization 
by Taraxacum officinale in normal and immune suppressed mice. Curr. Sci. 2016, 111, 
671-685. 
42. Tsai, K. L.; Kao, C. L.; Hung, C. H.; Cheng, Y. H.; Lin, H. C.; Chu, P. M., 
Chicoric acid is a potent anti-atherosclerotic ingredient by anti-oxidant action and anti-
inflammation capacity. Oncotarget 2017, 8, 29600-29612. 
43. Xue, Y. S.; Zhang, S. M.; Du, M.; Zhu, M. J., Dandelion extract suppresses 
reactive oxidative species and inflammasome in intestinal epithelial cells. J. Funct. Foods 
2017, 29, 10-18. 
44. Matthias, A.; Banbury, L.; Bone, K. M.; Leach, D. N.; Lehmann, R. P., Echinacea 
alkylamides modulate induced immune responses in T-cells. Fitoterapia 2008, 79, 53-58. 
 73 
 
 
45. Goel, V.; Chang, C.; Slama, J. V.; Barton, R.; Bauer, R.; Gahler, R.; Basu, T. K., 
Echinacea stimulates macrophage function in the lung and spleen of normal rats. J. Nutr. 
Biochem. 2002, 13, 487-492. 
46. Johnson, R. W., Inhibition of growth by pro-inflammatory cytokines: An 
integrated view. J. Aanim. Sci. 1997, 75, 1244-1255. 
47. Park, C. M.; Jin, K. S.; Lee, Y. W.; Song, Y. S., Luteolin and chicoric acid 
synergistically inhibited inflammatory responses via inactivation of PI3K-Akt pathway 
and impairment of NF-kappa B translocation in LPS stimulated RAW 264.7 cells. Eur. J. 
Pharmacol. 2011, 660, 454-459. 
48. Park, C. M.; Park, J. Y.; Noh, K. H.; Shin, J. H.; Song, Y. S., Taraxacum 
officinale Weber extracts inhibit LPS-induced oxidative stress and nitric oxide production 
via the NF-kappa B modulation in RAW 264.7 cells. J. Ethnopharmacol. 2011, 133, 834-
842. 
49. Gertsch, J.; Schoop, R.; Kuenzle, U.; Suter, A., Echinacea alkylamides modulate 
TNF-α gene expression via cannabinoid receptor CB2 and multiple signal transduction 
pathways. FEBS Letters 2004, 577, 563-569. 
50. Azay-Milhau, J.; Ferrare, K.; Leroy, J.; Aubaterre, J.; Tournier, M.; Lajoix, A. D.; 
Tousch, D., Antihyperglycemic effect of a natural chicoric acid extract of chicory 
(Cichorium intybus L.): A comparative in vitro study with the effects of caffeic and 
ferulic acids. Journal of Ethnopharmacology 2013, 150, 755-760. 
51. Zhu, D.; Wang, Y. T.; Du, Q. W.; Liu, Z. G.; Liu, X. B., Cichoric acid reverses 
insulin resistance and suppresses inflammatory responses in the glucosamine-induced 
HepG2 cells. J. Agric. Food Chem. 2015, 63, 10903-10913. 
52. Zhu, D.; Zhang, N.; Zhou, X. L.; Zhang, M. Y.; Liu, Z. G.; Liu, X. B., Cichoric 
acid regulates the hepatic glucose homeostasis via AMPK pathway and activates the 
antioxidant response in high glucose-induced hepatocyte injury. RSC Adv. 2017, 7, 1363-
1375. 
53. Dalar, A.; Konczak, I., Cichorium intybus from Eastern Anatolia: Phenolic 
composition, antioxidant and enzyme inhibitory activities. Ind. Crops Prod. 2014, 60, 79-
85. 
54. McCue, P.; Kwon, Y.-I.; Shetty, K., Anti-diabetic and anti-hypertensive potential 
of sprouted and solid-state bioprocessed soybean. Asia Pac. J. Clin. Nutr. 2005, 14, 145. 
55. Zhang, A. J.; Rimando, A. M.; Mizuno, C. S.; Mathews, S. T., α-Glucosidase 
inhibitory effect of resveratrol and piceatannol. J. Nutr. Biochem. 2017, 47, 86-93. 
 74 
 
 
56. Zhang, Z. Y., Protein tyrosine phosphatases: Prospects for therapeutics. Curr. 
Opin. Chem. Biol. 2001, 5, 416-423. 
57. Baskaran, S. K.; Goswami, N.; Selvaraj, S.; Muthusamy, V. S.; Lakshmi, B. S., 
Molecular dynamics approach to probe the allosteric inhibition of PTP1B by chlorogenic 
and cichoric acid. J. Chem. Inf. Model 2012, 52, 2004-2012. 
58. Lipchock, J. M.; Hendrickson, H. P.; Douglas, B. B.; Bird, K. E.; Ginther, P. S.; 
Rivalta, I.; Ten, N. S.; Batista, V. S.; Loria, J. P., Characterization of Protein Tyrosine 
Phosphatase 1B Inhibition by Chlorogenic Acid and Cichoric Acid. Biochemistry 2017, 
56, 96-106. 
59. Casanova, L. M.; da Silva, D.; Sola-Penna, M.; Camargo, L. M. D.; Celestrini, D. 
D.; Tinoco, L. W.; Costa, S. S., Identification of chicoric acid as a hypoglycemic agent 
from Ocimum gratissimum leaf extract in a biomonitoring in vivo study. Fitoterapia 
2014, 93, 132-141. 
60. Casanova, L. M.; Espindola-Netto, J. M.; Tinoco, L. W.; Sola-Penna, M.; Costa, S. 
S., The use of NMR metabolite profiling and in vivo hypoglycemic assay for comparison 
of unfractionated aqueous leaf extracts of two Ocimum species. Chem. Biodivers. 2016, 
13, 686-694. 
61. Zhu, D.; Zhang, X.; Niu, Y.; Diao, Z.; Ren, B.; Li, X.; Liu, Z.; Liu, X., Cichoric 
acid improved hyperglycaemia and restored muscle injury via activating antioxidant 
response in MLD-STZ-induced diabetic mice. Food Chem. Toxicol. 2017, 107, 138-149. 
62. Lyon, C. J.; Law, R. E.; Hsueh, W. A., Minireview: Adiposity, inflammation, and 
atherogenesis. Endocrinology 2003, 144, 2195-2200. 
63. Kim, M.; Yoo, G.; Randy, A.; Kim, H. S.; Nho, C. W., Chicoric acid attenuate a 
nonalcoholic steatohepatitis by inhibiting key regulators of lipid metabolism, fibrosis, 
oxidation, and inflammation in mice with methionine and choline deficiency. Mol. Nutr. 
Food Res. 2017, 61, 1-14. 
64. Xiao, H. F.; Xie, G.; Wang, J. W.; Hou, X. F.; Wang, X.; Wu, W. Q.; Liu, X. B., 
Chicoric acid prevents obesity by attenuating hepatic steatosis, inflammation and 
oxidative stress in high-fat diet-fed mice. Food Res. Int. 2013, 54, 345-353. 
65. Landmann, M.; Kanuri, G.; Spruss, A.; Stahl, C.; Bergheim, I., Oral intake of 
chicoric acid reduces acute alcohol-induced hepatic steatosis in mice. Nutrition 2014, 30, 
882-889. 
66. Kour, K.; Bani, S., Chicoric acid regulates behavioral and biochemical alterations 
induced by chronic stress in experimental Swiss albino mice. Pharmacol. Biochem. 
Behav. 2011, 99, 342-348. 
 75 
 
 
67. Ahn, H. R.; Lee, H. J.; Kim, K. A.; Kim, C. Y.; Nho, C. W.; Jang, H.; Pan, C. H.; 
Lee, C. Y.; Jung, S. H., Hydroxycinnamic acids in Crepidiastrum denticulatum protect 
oxidative stress-induced retinal damage. J. Agric. Food Chem. 2014, 62, 1310-1323. 
68. Ogomori, K.; Kitamoto, T.; Tateishi, J.; Sato, Y.; Suetsugu, M.; Abe, M., Beta-
protein amyloid is widely distributed in the central nervous system of patients with 
Alzheimer's disease. Am. J. Pathol. 1989, 134, 243. 
69. Bekinschtein, P.; Cammarota, M.; Katche, C.; Slipczuk, L.; Rossato, J. I.; Goldin, 
A.; Izquierdo, I.; Medina, J. H., BDNF is essential to promote persistence of long-term 
memory storage. PNAS 2008, 105, 2711-2716. 
70. Finkel, T.; Holbrook, N. J., Oxidants, oxidative stress and the biology of ageing. 
Nature 2000, 408, 239. 
71. Apel, K.; Hirt, H., Reactive oxygen species: metabolism, oxidative stress, and 
signal transduction. Annu. Rev. Plant Biol. 2004, 55, 373-399. 
72. Kimura, T.; Yamamoto, S.; Ogawa, I.; Miura, H.; Hasegawa, M., Antioxidant 
ability of chicoric acid and its analogous compounds. Nippon Kagaku Kaishi 1999, 739-
750. 
73. Schlernitzauer, A.; Oiry, C.; Hamad, R.; Galas, S.; Cortade, F.; Chabi, B.; Casas, 
F.; Pessemesse, L.; Fouret, G.; Feillet-Coudray, C.; Cros, G.; Cabello, G.; Magous, R.; 
Wrutniak-Cabello, C., Chicoric Acid Is an Antioxidant Molecule That Stimulates AMP 
Kinase Pathway in L6 Myotubes and Extends Lifespan in Caenorhabditis elegans. PloS 
one 2013, 8. 
74. Thygesen, L.; Thulin, J.; Mortensen, A.; Skibsted, L. H.; Molgaard, P., 
Antioxidant activity of cichoric acid and alkamides from Echinacea purpurea, alone and 
in combination. Food Chem. 2007, 101, 74-81. 
75. Wang, Y. T.; Diao, Z. J.; Li, J.; Ren, B.; Zhu, D.; Liu, Q.; Liu, Z. G.; Liu, X. B., 
Chicoric acid supplementation ameliorates cognitive impairment induced by oxidative 
stress via promotion of antioxidant defense system. RSC Adv. 2017, 7, 36149-36162. 
76. Liu, Q.; Wang, Y. T.; Xiao, C. X.; Wu, W. Q.; Liu, X. B., Metabolism of chicoric 
acid by rat liver microsomes and bioactivity comparisons of chicoric acid and its 
metabolites. Food Funct. 2015, 6, 1928-1935. 
77. Montagna, W.; Carlisle, K., Structural changes in aging human skin. J. Investig. 
Dermatol. 1979, 73, 47-53. 
78. Ma, Q., Role of nrf2 in oxidative stress and toxicity. Annu. Rev. Pharmacol. 
Toxicol. 2013, 53, 401-426. 
 76 
 
 
79. Valle, I.; Álvarez-Barrientos, A.; Arza, E.; Lamas, S.; Monsalve, M., PGC-1α 
regulates the mitochondrial antioxidant defense system in vascular endothelial cells. 
Cardiovasc. Res. 2005, 66, 562-573. 
80. Tsai, Y. L.; Chiu, C. C.; Yi-Fu Chen, J.; Chan, K. C.; Lin, S. D., Cytotoxic effects 
of Echinacea purpurea flower extracts and cichoric acid on human colon cancer cells 
through induction of apoptosis. J. Ethnopharmacol. 2012, 143, 914-919. 
81. Segueni, N.; Magid, A. A.; Decarme, M.; Rhouati, S.; Lahouel, M.; Antonicelli, 
F.; Lavaud, C.; Hornebeck, W., Inhibition of stromelysin-1 by caffeic acid derivatives 
from a propolis sample from Algeria. Planta. Medica. 2011, 77, 999-1004. 
82. Lin, Z. W.; Neamati, N.; Zhao, H.; Kiryu, Y.; Turpin, J. A.; Aberham, C.; Strebel, 
K.; Kohn, K.; Witvrouw, M.; Pannecouque, C.; Debyser, Z.; De Clercq, E.; Rice, W. G.; 
Pommier, Y.; Burke, T. R., Chicoric acid analogues as HIV-1 integrase inhibitors. J. Med. 
Chem. 1999, 42, 1401-1414. 
83. Pluymers, W.; Neamati, N.; Pannecouque, C.; Fikkert, V.; Marchand, C.; Burke, 
T. R.; Pommier, Y.; Schols, D.; De Clercq, E.; Debyser, Z.; Witvrouw, M., Viral entry as 
the primary target for the anti-HIV activity of chicoric acid and its tetra-acetyl esters. Mol. 
Pharmacol. 2000, 58, 641-648. 
84. Dalby-Brown, L.; Barsett, H.; Landbo, A. K. R.; Meyer, A. S.; Molgaard, P., 
Synergistic antioxidative effects of alkamides, caffeic acid derivatives, and 
polysaccharide fractions from Echinacea purpurea on in vitro oxidation of human low-
density lipoproteins. J. Agric. Food Chem. 2005, 53, 9413-9423. 
85. Chen, L. X.; Huang, G.; Gao, M.; Shen, X. D.; Gong, W.; Xu, Z. Z.; Zeng, Y. J.; 
He, F. T., Chicoric acid suppresses BAFF expression in B lymphocytes by inhibiting NF-
kappa B activity. Int. Immunopharmacol. 2017, 44, 211-215. 
86. Zhang, H. L.; Dai, L. H.; Wu, Y. H.; Yu, X. P.; Zhang, Y. Y.; Guan, R. F.; Liu, T.; 
Zhao, J., Evaluation of hepatocyteprotective and anti-hepatitis B virus properties of 
cichoric acid from Cichorium intybus leaves in cell culture. Biol. Pharm. Bull. 2014, 37, 
1214-1220. 
87. Huntimer, E. D.; Halaweish, F. T.; Chase, C. C. L., Proliferative activity of 
Echinacea angustifolia root extracts on cancer cells: Interference with doxorubicin 
cytotoxicity. Chem. Biodivers. 2006, 3, 695-703. 
88. Kour, K.; Bani, S., Augmentation of immune response by chicoric acid through 
the modulation of CD28/CTLA-4 and Th1 pathway in chronically stressed mice. 
Neuropharmacology 2011, 60, 852-860. 
 77 
 
 
89. Lee, N. Y.; Chung, K. S.; Jin, J. S.; Bang, K. S.; Eom, Y. J.; Hong, C. H.; 
Nugroho, A.; Park, H. J.; An, H. J., Effect of chicoric acid on mast cell-mediated allergic 
inflammation in vitro and in vivo. J. Nat. Prod. 2015, 78, 2956-2962. 
90. Perkins, N. D., Integrating cell-signalling pathways with NF-κB and IKK function. 
Nat. Rev. Mol. Cell Bio. 2007, 8, 49. 
91. Wang, Y. T.; Xie, G.; Liu, Q.; Duan, X.; Liu, Z. G.; Liu, X. B., Pharmacokinetics, 
tissue distribution, and plasma protein binding study of chicoric acid by HPLC-MS/MS. J. 
Chromatogr. B 2016, 1031, 139-145. 
92. Lee, K. S.; Lee, B. S.; Semnani, S.; Avanesian, A.; Um, C. Y.; Jeon, H. J.; Seong, 
K. M.; Yu, K.; Min, K. J.; Jafari, M., Curcumin extends life span, improves health span, 
and modulates the expression of age-associated aging genes in Drosophila melanogaster. 
Rejuvenation Res. 2010, 13, 561-570. 
93. Rathor, L.; Akhoon, B. A.; Pandey, S.; Srivastava, S.; Pandey, R., Folic acid 
supplementation at lower doses increases oxidative stress resistance and longevity in 
Caenorhabditis elegans. Age 2015, 37, 113. 
94. Shen, P.; Yue, Y.; Sun, Q.; Kasireddy, N.; Kim, K. H.; Park, Y., Piceatannol 
extends the lifespan of Caenorhabditis elegans via DAF-16. BioFactors 2017, 43, 379-
387. 
95. Zheng, S. Q.; Huang, X. B.; Xing, T. K.; Ding, A. J.; Wu, G. S.; Luo, H. R., 
Chlorogenic acid extends the lifespan of Caenorhabditis elegans via insulin/IGF-1 
signaling pathway. J. Gerontol. A. Biol. Sci. Med. Sci. 2017, 72, 464-472. 
96. Hart, A. C.; Onken, B.; Driscoll, M., Metformin induces a dietary restriction–like 
state and the oxidative stress response to extend C. elegans healthspan via AMPK, LKB1, 
and SKN-1. PloS one 2010, 5, e8758. 
97. Hwang, A. B.; Ryu, E.-A.; Artan, M.; Chang, H.-W.; Kabir, M. H.; Nam, H.-J.; 
Lee, D.; Yang, J.-S.; Kim, S.; Mair, W. B., Feedback regulation via AMPK and HIF-1 
mediates ROS-dependent longevity in Caenorhabditis elegans. PNAS 2014, 111, 4458-
4467. 
98. Salminen, A.; Kaarniranta, K., AMP-activated protein kinase (AMPK) controls 
the aging process via an integrated signaling network. Ageing Res. Rev. 2012, 11, 230-
241. 
99. Tullet, J. M.; Hertweck, M.; An, J. H.; Baker, J.; Hwang, J. Y.; Liu, S.; Oliveira, 
R. P.; Baumeister, R.; Blackwell, T. K., Direct inhibition of the longevity-promoting 
factor SKN-1 by insulin-like signaling in C. elegans. Cell 2008, 132, 1025-1038. 
 78 
 
 
100. Stiernagle, T., Maintenance of C. elegans. WormBook : the online review of C. 
elegans biology 2006, 1-11. 
101. Sun, Q.; Yue, Y.; Shen, P.; Yang, J. J.; Park, Y., Cranberry product decreases fat 
accumulation in Caenorhabditis elegans. J. Med. Food 2016, 19, 427-433. 
102. Shen, P.; Yue, Y.; Zheng, J.; Park, Y., Caenorhabditis elegans: A convenient in 
vivo model for assessing the impact of food bioactive compounds on obesity, aging, and 
Alzheimer's disease. Annu. Rev. Food Sci. Technol. 2018, 9, 1-22. 
103. Yue, Y.; Shen, P.; Xu, Y.; Park, Y., p-Coumaric acid improves oxidative and 
osmosis stress responses in Caenorhabditis elegans. J. Sci. Food Agric. 2018, 99, 1190-
1197. 
104. Colmenares, D.; Sun, Q.; Shen, P.; Yue, Y.; McClements, D. J.; Park, Y., 
Delivery of dietary triglycerides to Caenorhabditis elegans using lipid nanoparticles: 
Nanoemulsion-based delivery systems. Food Chem. 2016, 202, 451-457. 
105. Chen, Y.; Onken, B.; Chen, H.; Xiao, S.; Liu, X.; Driscoll, M.; Cao, Y.; Huang, 
Q., Mechanism of longevity extension of Caenorhabditis elegans induced by 
pentagalloyl glucose isolated from eucalyptus leaves. J Agric. Food Chem. 2014, 62, 
3422-3431. 
106. Jeong, D. E.; Lee, Y.; Lee, S. J. V., Western blot analysis of C. elegans proteins. 
In Hypoxia, Springer: 2018; pp 213-225. 
107. Sun, Q.; Zhang, Z.; Zhang, R.; Gao, R.; McClements, D. J., Development of 
functional or medical foods for oral administration of insulin for diabetes treatment: 
Gastroprotective edible microgels. J Agric. Food Chem. 2018, 66, 4820-4826. 
108. Apfeld, J.; O'Connor, G.; McDonagh, T.; DiStefano, P. S.; Curtis, R., The AMP-
activated protein kinase AAK-2 links energy levels and insulin-like signals to lifespan in 
C. elegans. Gene Dev. 2004, 18, 3004-3009. 
109. Mair, W.; Morantte, I.; Rodrigues, A. P.; Manning, G.; Montminy, M.; Shaw, R. 
J.; Dillin, A., Lifespan extension induced by AMPK and calcineurin is mediated by 
CRTC-1 and CREB. Nature 2011, 470, 404. 
110. Sagi, D.; Kim, S. K., An engineering approach to extending lifespan in C. elegans. 
PLoS Genet. 2012, 8, e1002780. 
111. Kenyon, C.; Chang, J.; Gensch, E.; Rudner, A.; Tabtiang, R., A C. elegans mutant 
that lives twice as long as wild type. Nature 1993, 366, 461. 
 79 
 
 
112. Kimura, K. D.; Tissenbaum, H. A.; Liu, Y.; Ruvkun, G., daf-2, an insulin 
receptor-like gene that regulates longevity and diapause in Caenorhabditis elegans. 
Science 1997, 277, 942-946. 
113. Dorman, J. B.; Albinder, B.; Shroyer, T.; Kenyon, C., The Age-1 and Daf-2 genes 
function in a common pathway to control the lifespan of Caenorhabditis elegans. 
Genetics 1995, 141, 1399-1406. 
114. Vowels, J. J.; Thomas, J. H., Genetic analysis of chemosensory control of dauer 
formation in Caenorhabditis elegans. Genetics 1992, 130, 105-123. 
115. An, J. H.; Blackwell, T. K., SKN-1 links C. elegans mesendodermal specification 
to a conserved oxidative stress response. Gene Dev. 2003, 17, 1882-1893. 
116. Bowerman, B.; Eaton, B. A.; Priess, J. R., skn-1, a maternally expressed gene 
required to specify the fate of ventral blastomeres in the early C. elegans embryo. Cell 
1992, 68, 1061-1075. 
117. Lakowski, B.; Hekimi, S., The genetics of caloric restriction in Caenorhabditis 
elegans. PNAS 1998, 95, 13091-13096. 
118. Chang, H. W.; Pisano, S.; Chaturbedi, A.; Chen, J.; Gordon, S.; Baruah, A.; Lee, 
S. S., Transcription factors CEP‐1/p53 and CEH‐23 collaborate with AAK‐2/AMPK 
to modulate longevity in Caenorhabditis elegans. Aging Cell 2017, 16, 814-824. 
119. Lee, H.; Cho, J. S.; Lambacher, N.; Lee, J.; Lee, S. J.; Lee, T. H.; Gartner, A.; 
Koo, H. S., The Caenorhabditis elegans AMP-activated protein kinase AAK-2 is 
phosphorylated by LKB1 and is required for resistance to oxidative stress and for normal 
motility and foraging behavior. J. Biol. Chem. 2008, 283, 14988-14993. 
120. Moreno-Arriola, E.; Hafidi, M. E.; Ortega-Cuéllar, D.; Carvajal, K., AMP-
activated protein kinase regulates oxidative metabolism in Caenorhabditis elegans 
through the NHR-49 and MDT-15 transcriptional regulators. PloS one 2016, 11, 
e0148089. 
121. Li, H.; Liu, X.; Wang, D.; Su, L.; Zhao, T.; Li, Z.; Lin, C.; Zhang, Y.; Huang, B.; 
Lu, J., O-GlcNAcylation of SKN-1 modulates the lifespan and oxidative stress resistance 
in Caenorhabditis elegans. Sci. Rep. 2017, 7, 43601. 
122. Blackwell, T. K.; Steinbaugh, M. J.; Hourihan, J. M.; Ewald, C. Y.; Isik, M., 
SKN-1/Nrf, stress responses, and aging in Caenorhabditis elegans. Free Radic. Biol. Med. 
2015, 88, 290-301. 
123. Chondrogianni, N.; Georgila, K.; Kourtis, N.; Tavernarakis, N.; Gonos, E. S., 20S 
proteasome activation promotes life span extension and resistance to proteotoxicity in 
 80 
 
 
Caenorhabditis elegans. FASEB journal : official publication of the Federation of 
American Societies for Experimental Biology 2015, 29, 611-622. 
124. Lüersen, K.; Stegehake, D.; Daniel, J.; Drescher, M.; Ajonina, I.; Ajonina, C.; 
Hertel, P.; Woltersdorf, C.; Liebau, E., The glutathione reductase GSR-1 determines 
stress tolerance and longevity in Caenorhabditis elegans. PloS one 2013, 8, e60731. 
125. Harman, D., Aging: A theory based on free radical and radiation chemistry. Sci. 
Aging Knowledge Environ. 2002, 2002, 14. 
126. Maeda, A.; Kai, K.; Ishii, M.; Ishii, T.; Akagawa, M., Safranal, a novel protein 
tyrosine phosphatase 1 B inhibitor, activates insulin signaling in C2C12 myotubes and 
improves glucose tolerance in diabetic KK‐Ay mice. Mol. Nutr. Food Res. 2014, 58, 
1177-1189. 
127. Sykiotis, G. P.; Bohmann, D., Stress-activated cap'n'collar transcription factors in 
aging and human disease. Sci. Signal. 2010, 3, 1-45. 
128. An, J. H.; Vranas, K.; Lucke, M.; Inoue, H.; Hisamoto, N.; Matsumoto, K.; 
Blackwell, T. K., Regulation of the Caenorhabditis elegans oxidative stress defense 
protein SKN-1 by glycogen synthase kinase-3. PNAS 2005, 102, 16275-16280. 
129. Palikaras, K.; Lionaki, E.; Tavernarakis, N., Coordination of mitophagy and 
mitochondrial biogenesis during ageing in C. elegans. Nature 2015, 521, 525. 
130. Bjornholm, M.; Zierath, J. R., Insulin signal transduction in human skeletal 
muscle: identifying the defects in type II diabetes. Biochem. Soci. Transact. 2005, 33, 
354–357. 
131. Kahn, S. E.; Hull, R. L.; Utzschneider, K. M., Mechanisms linking obesity to 
insulin resistance and type 2 diabetes. Nature 2006, 444, 840-846. 
132. Wijesekara, N.; Thong, F. S. L.; Anonescu, C. N.; Klip, A., Diverse signals 
regulate glucose uptake into skeletal muscle. Can. J. Diabetes 2006, 30, 80–88. 
133. Carling, D., The AMP-activated protein kinase cascade--a unifying system for 
energy control. Trends Biochem. Sci. 2004, 29, 18-24. 
134. Fujii, N.; Jessen, N.; Goodyear, L. J., AMP-activated protein kinase and the 
regulation of glucose transport. Am. J. Physiol. Endocrinol. Metab. 2006, 291, 867-877. 
135. Chopra, I.; Li, H. F.; Wang, H.; Webster, K. A., Phosphorylation of the insulin 
receptor by AMP-activated protein kinase (AMPK) promotes ligand-independent 
activation of the insulin signalling pathway in rodent muscle. Diabetologia 2012, 55, 
783-794. 
 81 
 
 
136. Tao, R.; Gong, J.; Luo, X.; Zang, M.; Guo, W.; Wen, R.; Luo, Z., AMPK exerts 
dual regulatory effects on the PI3K pathway. J. Mol. Signal. 2010, 5, 1-9. 
137. Meng, S.; Cao, J.; Feng, Q.; Peng, J.; Hu, Y., Roles of chlorogenic acid on 
regulating glucose and lipids metabolism: A review. Evid-Based Compl. Alt. 2013, 2013, 
1-11. 
138. Innocenti, M.; Gallori, S.; Giaccherini, C.; Ieri, F.; Vincieri, F. F.; Mulinacci, N., 
Evaluation of the phenolic content in the aerial parts of different varieties of Cichorium 
intybus L. J. Agric. Food Chem. 2005, 53, 6497–6502. 
139. Lee, J.; Scagel, C. F., Chicoric acid found in basil (Ocimum basilicum L.) leaves. 
Food Chem. 2009, 115, 650-656. 
140. DeFronzo, R. A.; Gunnarsson, R.; Bjorkman, O.; Olsson, M.; Wahren, J., Effects 
of insulin on peripheral and splanchnic glucose metabolism in noninsulin-dependent 
(type II) diabetes mellitus. J. Clinic. Investig. 1985, 76, 149–155. 
141. Deshmukh, A. S.; Murgia, M.; Nagaraj, N.; Treebak, J. T.; Cox, J.; Mann, M., 
Deep proteomics of mouse skeletal muscle enables quantitation of protein isoforms, 
metabolic pathways, and transcription factors. Mol. Cell. Proteom. 2015, 14, 841-853. 
142. Sharples, A. P.; Al-Shanti, N.; Stewart, C. E., C2 and C2C12 murine skeletal 
myoblast models of atrophic and hypertrophic potential: relevance to disease and aging. J. 
Cell. Physiol. 2010, 225, 240–250. 
143. Kim, J.; Park, Y.; Yoon, K. S.; Clark, J. M.; Park, Y., Permethrin alters 
adipogenesis in 3T3-L1 adipocytes and causes insulin resistance in C2C12 myotubes. J. 
Biochem. Mol. Toxicol. 2014, 28, 418-424. 
144. Zhou, G.; Myers, R.; Li, Y.; Chen, Y.; Shen, X.; Fenyk-Melody, J.; Wu, M.; 
Ventre, J.; Doebber, T.; Fujii, N.; Musi, N.; Hirshman, M. F.; Goodyear, L. J.; Moller, D. 
E., Role of AMP-activated protein kinase in mechanism of metformin action. J. Clinic. 
Invest. 2001, 108, 1167-1174. 
145. Xiao, H.; Wang, J.; Yuan, L.; Xiao, C.; Wang, Y.; Liu, X., Chicoric acid induces 
apoptosis in 3T3-L1 preadipocytes through ROS-mediated PI3K/Akt and MAPK 
signaling pathways. Journal of Agriculture and Food Chemistry 2013, 61, 1509-1520. 
146. Osorio-Fuentealba, C.; Contreras-Ferrat, A. E.; Altamirano, F.; Espinosa, A.; Li, 
Q.; Niu, W.; Lavandero, S.; Klip, A.; Jaimovich, E., Electrical stimuli release ATP to 
increase GLUT4 translocation and glucose uptake via PI3Kγ-Akt-AS160 in skeletal 
muscle cells. Diabetes 2013, 62, 1519-1526. 
 82 
 
 
147. Huang, Z.; Xie, X., Chemerin induces insulin resistance in C2C12 cells through 
nuclear factor-kappaB pathway-mediated inflammatory reaction. Chinese J. Cell. Mol. 
Immun. 2015, 31, 725-729. 
148. Sun, Q.; Peng, Y.; Qi, W.; Kim, Y.; Clark, J. M.; Kim, D.; Park, Y., Permethrin 
decreased insulin-stimulated AKT phosphorylation dependent on extracellular signal-
regulated kinase-1 (ERK), but not AMP-activated protein kinase alpha (AMPKalpha), in 
C2C12 myotubes. Food Chem. Toxicol. 2017, 109, 95-101. 
149. Kim, S.; Go, G. W.; Imm, J. Y., Promotion of glucose uptake in C2C12 myotubes 
by Cereal Flavone Tricin and its underlying molecular mechanism. J. Agric. Food Chem. 
2017, 65, 3819-3826. 
150. Sun, C.; Zhang, F.; Ge, X.; Yan, T.; Chen, X.; Shi, X.; Zhai, Q., SIRT1 improves 
insulin sensitivity under insulin-resistant conditions by repressing PTP1B. Cell Metab. 
2007, 6, 307-319. 
151. Sun, Q.; Qi, W.; Xiao, X.; Yang, S. H.; Kim, D.; Yoon, K. S.; Clark, J. M.; Park, 
Y., Imidacloprid promotes high fat diet-induced adiposity in female C57BL/6J mice and 
enhances adipogenesis in 3T3-L1 adipocytes via the AMPKalpha-mediated pathway. J. 
Agric. Food Chem. 2017, 65, 6572-6581. 
152. Azay-Milhau, J.; Ferrare, K.; Leroy, J.; Aubaterre, J.; Tournier, M.; Lajoix, A. D.; 
Tousch, D., Antihyperglycemic effect of a natural chicoric acid extract of chicory 
(Cichorium intybus L.): A comparative in vitro study with the effects of caffeic and 
ferulic acids. J. Ethnopharmacol. 2013, 150, 755-760. 
153. García-Vicente, S.; Yraola, F.; Marti, L.; González-Muñoz, E.; García-Barrado, 
M. J.; Cantó, C.; Abella, A.; Bour, S.; Artuch, R.; Sierra, C.; Brandi, N.; Carpéné, C.; 
Moratinos, J.; Camps, M.; Palacín, M.; Testar, X.; Gumà, A.; Albericio, F.; Royo, M.; 
Mian, A.; Zorzano, A., Oral insulin-mimetic compounds that act independently of insulin. 
Diabetes 2007, 56, 486-493. 
154. Wan, Z.; Root-McCaig, J.; Castellani, L.; Kemp, B. E.; Steinberg, G. R.; Wright, 
D. C., Evidence for the role of AMPK in regulating PGC-1 alpha expression and 
mitochondrial proteins in mouse epididymal adipose tissue. Obesity 2014, 22, 730-738. 
155. Canto, C.; Auwerx, J., PGC-1alpha, SIRT1 and AMPK, an energy sensing 
network that controls energy expenditure. Curr. Opin. Lipidol. 2009, 20, 98-105. 
156. Eid, H. M.; Vallerand, D.; Muhammad, A.; Durst, T.; Haddad, P. S.; Martineau, L. 
C., Structural constraints and the importance of lipophilicity for the mitochondrial 
uncoupling activity of naturally occurring caffeic acid esters with potential for the 
treatment of insulin resistance. Biochem. Pharmacol. 2010, 79, 444-454. 
 83 
 
 
157. Lee, E. S.; Uhm, K.; Lee, Y. M.; Han, M.; Lee, M.; Park, J. M.; Suh, P.; Park, S.; 
Kim, H. S., CAPE (caffeic acid phenethyl ester) stimulates glucose uptake through 
AMPK (AMP-activated protein kinase) activation in skeletal muscle cells. Biochem. 
Biophys. Res. Commun. 2007, 361, 854-858. 
 
